

https://dspace.org/

# Brain concentrations and the neurochemical effects of passively administered fluoxetine in Flinders sensitive line rat offspring

**Steyn, Stephanus Frederik**

**2023**

University of the Witwatersrand, Johannesburg

https://hdl.handle.net/10539/43193

Steyn, Stephanus Frederik. (2023). Brain concentrations and the neurochemical effects of passively administered fluoxetine in Flinders sensitive line rat offspring [Master's dissertation PhD thesis, University of the Witwatersrand, Johannesburg].https://hdl.handle.net/10539/43193

Downloaded from a DSpace repository. https://dspace.org/




# Brain concentrations and the neurochemical effects of passively administered fluoxetine in Flinders sensitive line rat offspring

by

SF Steyn

*BPharm (PCDT | PIMART); MSc; PhD (Pharmacology)*

**(2632279)**

**Research report**

Submitted in partial fulfilment of the requirements for the degree

**Master of Science in Medicine**

in

**Clinical Pharmacy**

in the Faculty of Science, University of the Witwatersrand, Johannesburg, South Africa

Supervisor: Prof P Kondiah

*Hons; MSc-PhD; MBA; Pearson College London Alumni*

Co-supervisor: Prof N Padayachee

*BSc; BPharm; MPharm; PhD*

November 2023

# DECLARATION

I, Stephan Steyn, hereby declare that all experimental work, planning, literature research, data analyses, interpretation, and writing this dissertation was done by myself. This project was funded by research funds awarded to me by the North-West University and approved by the necessary Ethics and Research committees. All neurochemical analyses were performed by me, with the assistance of Doctor Francois Viljoen of the North-West University, Pharmacen research entity. All statistical analyses were also performed by myself.

I also declare that:

- I am aware that plagiarism is wrong, and have therefore subjected this report to a similarity comparison, of which the summary report is available in Addendum B.
- I confirm that the work submitted for assessment for the degree mentioned on the cover page (Master of Science in Clinical Pharmacy) is my own unaided work (except for the above-mentioned assistance).
- I have followed the required conventions in referencing the thoughts and ideas of others.
- I understand that the University of the Witwatersrand may take disciplinary action against me if there is a belief that this is not my own unaided work, or that I have failed to acknowledge the source of the ideas or words in my writing.

Stephanus F Steyn

# ABSTRACT

**Background:** Globally, 36 % of women who have recently given birth, experience symptoms of depression and anxiety. Effective antidepressant treatments are limited, with fluoxetine being a popular treatment option. Fluoxetine is expressed in the breast milk, yet it is unclear to what extent fluoxetine, or its active metabolite, norfluoxetine, reaches the brain of the developing child and what the effects of such exposure on the related neurobiological processes would be. Due to ethical considerations and practical restrictions, clinical investigations into the neurodevelopmental effects of passively administered antidepressants (via the breast milk) are problematic. Therefore, pre-clinical investigations into this topic are not only important but clinically relevant. **Aims & objectives:** We aimed to quantify the concentration of passively administered, i.e., via the breast milk during nursing, fluoxetine, and its active metabolite, norfluoxetine in the whole brains of exposed Flinders sensitive line (FSL) rats (an established rodent model of depression). We further aimed to establish if said exposure would associate with changes in whole-brain serotonergic function and redox status. **Methods:** Adult FSL dams received fluoxetine (10 mg/kg/day), or placebo for fourteen days, beginning on postpartum day 04. Offspring (*n* = 16 per exposure group; 1:1 male: female) were passively exposed to fluoxetine until postnatal day 18 and euthanized on postnatal day 22. Whole brain fluoxetine, norfluoxetine, serotonin, 5-hydroxyindoleacetic acid (5-HIAA), and reduced and oxidized glutathione (GSH and GSSG) concentrations were measured via liquid chromatography/mass spectrometry (LC-MS). **Results:** Fluoxetine, was undetectable in the brain of FSL offspring, while norfluoxetine concentrations, averaged 41.28 ± 6.47 ng/g. Neither serotonin, nor its metabolite (5-HIAA), was affected by passively administered fluoxetine in the juvenile brain. In terms of redox status, pups exposed to fluoxetine presented with a compromised antioxidant defence, as evinced by a lower GSH/GSSG ratio. **Discussion and conclusion:** Although fluoxetine and norfluoxetine concentrations have been measured in breast milk and infant plasma, to the best of our knowledge, it has not been quantified in the juvenile brain until now. Our results are in line with clinical findings, suggesting the infant norfluoxetine/fluoxetine ratio to be elevated, probably because of the prolonged half-life of norfluoxetine. Although only norfluoxetine was detected, this did not influence the central serotonin concentrations of offspring. However, it associated with increased oxidative stress, of which the pathophysiological significance remains to be established. Taken together, our findings confirm that passively administered fluoxetine does reach the infant brain in the form of norfluoxetine and may manipulate processes of oxidative stress regulation. Further studies into the long-term bio-behavioural effects are however needed to effectively inform breast feeding mothers on the safety of antidepressant-use during the postpartum period.

**Keywords**

Breast milk; Flinders resistant line (FRL); Flinders sensitive line (FSL); Norfluoxetine; Oxidative stress

**Highlights**

- Passively administered fluoxetine results in detectable concentrations of norfluoxetine, but not fluoxetine, in whole brains of pre-pubertal male and female FSL rats.
- Serotonergic metabolism and concentrations are unaffected by chronic passively administered fluoxetine.
- Pre-pubertal male and female FSL rats have reduced whole antioxidant defences (GSH/GSSG), compared to age matched FRL controls.
- This GSH/GSSG imbalance is further reduced by chronic passively administered fluoxetine.

**Limitations**

- The body weight of the pups was not available to validate whether brain weights were indeed comparable across the different experimental groups.
- Because only GSH and GSSG concentrations were measured, concluding on whether the observed redox state differences are indeed detrimental to juvenile development, remains to be confirmed.
- That no behavioural analyses could be performed, further limits the interpretation of the nature of these results.

**List of abbreviations**

**5-HIAA:** 5-hydroxyindoleacetic acid; **5-HT:** 5-hydroxytryptamine (serotonin); **8-OHdG:** 8-hydroxy-2'-deoxyguanosine; **ACN:** Acetonitrile; **ATP:** Adenosine triphosphate; **BDNF:** Brain-derived neurotrophic factor; **CRH:** Corticotropin-releasing hormone; **DNA:** Deoxyribonucleic acid; **DSM-V:** Diagnostic and statistical manual of mental disorders, 5$^{th}$ edition; $\boldsymbol{d_{unb}}$**:** Unbiased Cohen's *d*-value; **FLX:** Fluoxetine; **FRL:** Flinders resistant line; **FSL:** Flinders sensitive line; **GABA:** Gamma aminobutyric acid; **GSH:** Glutathione (reduced); **GSSG:** Glutathione disulphide (oxidized); **HPA:** Hypothalamic-pituitary-adrenal; **nFLX:** Norfluoxetine; **NWU:** North-West University; **PND:** Postnatal day; **PPD:** Postpartum day; **SSRI:** Selective serotonin re-uptake inhibitor; **Wits:** University of the Witwatersrand.

*Dedicated to my parents, wife and two hooligans*

# ACKNOWLEDGEMENTS

To **Jesus Christ**, thank you for giving me the ability, courage, and support to take on this challenge. Thank you for carrying me through the difficult times and keeping me safe on the road between Potch and Johannesburg.

My loving and supporting wife, **Zilla**. I would never have been able to complete this chapter without your support, and more importantly, knowing that you have everything under control at home and in our lives. You are my best friend and I hope that we will grow old together and keep on enjoying each other's company and jokes. You inspire me to be a better person, father, and friend. Thank you for always motivating me and supporting whatever endeavour I take on. To my children, **Alexa, and Steph** – you light up my life and make me work harder than what I ever thought possible. I hope that you will surpass any achievement that your mom and I may ever reach. I love you three.

**De Wet**, **Ansa** and **Prof Linda** – I cannot put into words how much I appreciate you and how thankful I am for the support during the last two years. Ansa, for being a special friend to Zilla, and supporting her when I was on the road. De Wet and Prof Linda, you took a chance on a young lecturer years ago. I hope that I have lived up to your expectations – I know that I would not have been the person, pharmacist, and researcher I am today, without your support and trust over the years.

My mom, **Martinette** and **Olof** – you never doubted me when I told you that I am registering for a master's degree, while Zilla completed her postgraduate diploma, and the two hooligans were running around the house. You always supported us and loved us no matter the situation. Thank you for everything you do and what you have taught us. My sister (**Anzelle**) and brother (**Martin**), thank you for being a phone call away and always willing to listen. I love you all.

My late father, **Ferdie Steyn** – Dad, you instilled a love for knowledge in us. Although you are no longer here to see us reach new heights, we take on these challenges to stay close to you. I know you would have been proud.

To my supervisors, **Pierre** and **Neelaveni** – thank you for allowing me to work with you. Although this relationship was mainly limited to Whatsapp messages and emails, I am sure that this friendship will carry on for years to come. I am grateful for the opportunity to get to know you both.

**Jaco** and **Jeanette Visagie**, and **Elke Human** – karate has and will always be part of me. Through the training sessions and coffee discussions, you kept me motivated, kept the Dojo running smoothly, and strengthened my character, and fighting spirit (on and off the *tatami*). You will never realize how much I look up to you. *Domo arigato gozaimasu*.

**Francois Viljoen** and **Henrico Heystek** – you to never hesitated to drop in for a coffee to take my mind of the work. It may not have seemed like it at the moment but looking back, these breaks helped me appreciate people like you in my life. Thank you very much.

**Daniël van Rensburg**, **Ashleigh Whitney**, **Mareli Roets**, **Henlo Oosthuizen** and **Charné Botha** – you were all there when I took on this degree. You encouraged me when I needed it and never complained when I didn't send you your feedback on time. Thank you for being my friends. To Daniël and Ash, you are probably the two people in my life that intellectually challenge me in such a way that I will never stop reading and learning. Thank you for this – it helped me during this chapter of my life.

# TABLE OF CONTENTS

**DECLARATION** ..... **I**

**ABSTRACT** ..... **II**

**HIGHLIGHTS** ..... **III**

**LIMITATIONS** ..... **III**

**ACKNOWLEDGEMENTS** ..... **V**

**CHAPTER 1: INTRODUCTION** ..... **1**

**1.1 Dissertation layout** ..... **1**

**1.2 Background and problem statement** ..... **2**

**1.3 Research question** ..... **5**

**1.4 Study aims and objectives** ..... **6**

**1.5 Hypothesis** ..... **6**

**1.6 Study design and layout** ..... **7**

**1.7 Justification of group sizes** ..... **8**

**1.8 Translatability of the findings and predicted impact** ..... **8**

**1.9 Ethical considerations and approval** ..... **9**

**CHAPTER 2: LITERATURE REVIEW** ..... **10**

**2.1 Epidemiology of postpartum depression** ..... **10**

**2.2 Aetiology of postpartum depression** ..... **12**

**2.3 Signs and symptoms and the impact on mother-child relationships** ..... **14**

**2.4 Treating postpartum depression** ..... **16**

2.4.1 General approach to treatment during the postpartum period ..... 16

2.4.1.1 Brexanolone ..... 17

2.4.1.2 Fluoxetine ..... 19

**2.5 Pharmacological treatment options and the impact on the developing infant brain** ..... **20**

2.5.1 Juvenile brain development ..... 20

2.5.2 Bio-behavioural effects of early-life exposure to antidepressants ..... 22

**2.6 The Flinders sensitive line rat as a suitable rodent model ..... 24**

**CHAPTER 3: MATERIALS AND METHODS FOR NEUROCHEMICAL ANALYSES ..... 26**

**3.1 Where tissue was sampled from ..... 26**

**3.2 Sample preparation ..... 26**

**3.3 Method validation ..... 27**

3.3.1 Standard solutions ..... 27

3.3.2 Internal standard solution ..... 27

3.3.3 Mobile phase ..... 27

3.3.4 Multiple reaction monitoring optimisation ..... 28

3.3.5 Linearity and calibration curve ..... 29

3.3.6 Quantification and detection limits ..... 29

3.3.7 Precision and accuracy ..... 29

3.3.8 Stability ..... 29

**3.4 Method validation results ..... 30**

3.4.1 Quantification and detection limits ..... 30

3.4.2 Precision and accuracy ..... 31

3.4.3 Percentage recovery and stability ..... 33

**CHAPTER 4: RESULTS AND DISCUSSION ..... 34**

**4.1 Statistical analyses ..... 34**

**4.2 Results ..... 34**

4.2.1 Whole brain fluoxetine and norfluoxetine concentrations ..... 35

4.2.2 Serotonin and 5-hydroxyindoleacetic acid ..... 36

4.2.3 Redox markers ..... 37

**4.3 Discussion ..... 39**

4.3.1 Model validation (FSL *vs.* FRL) ..... 39

4.3.2 The fluoxetine effect ..... 40

**CHAPTER 5: CONCLUSION, LIMITATIONS, AND FUTURE RESEARCH RECOMMENDATIONS ..... 44**

**5.1 Conclusion ..... 45**

**5.2 Limitations and future recommendations ..... 45**

**ADDENDUM A: ETHICAL APPROVAL ..... 47**

**ADDENDUM B: TURNITIN SUMMARY REPORT ..... 53**

**REFERENCES ..... 54**

# LIST OF TABLES

Table 1-1: Study aims and objectives ..... 6

Table 1-2: Summary of power analyses performed, justifying the experimental group sizes ..... 8

Table 1-3: ARRIVE Essential 10 ..... 9

Table 2-1: Diagnostic criteria of major depressive disorder, according to the Diagnostic and statistical manual of mental disorders, 5th edition (DSM-V) (adapted from American Psychiatric Association, 2013b) ..... 14

Table 3-1: Mobile phase gradient setup ..... 27

Table 3-2: Optimum instrument settings for the identification and quantification of product ions ..... 28

Table 3-3: Linear regression line equation and coefficient of determination ($R^2$) ..... 30

Table 3-4: Limits of quantification and detection results ..... 31

Table 3-5: Accuracy and precision results ..... 32

Table 3-6: Percentage recovery results ..... 33

Table 4-1: Descriptive statistics of the brain weight data of the different experimental groups ..... 35

Table 4-2: Summary of serotonergic markers in the whole brain of FSL and FRL juvenile rats ..... 36

Table 4-3: Summary of redox markers in the whole brain of FSL and FRL juvenile rats ..... 38

# LIST OF FIGURES

Figure 1-1: Graphical representation of study layout ..... 7

Figure 2-1: Summarized comparison of rodent and human developmental phases ..... 21

Figure 4-1: Whole brain serotonin turnover of FSL and FRL rats ..... 37

Figure 4-2: Whole brain redox status of FSL and FRL rats ..... 38

# CHAPTER 1: INTRODUCTION

## 1.1 Dissertation layout

The study rationale, methodology, findings, and discussion thereof are presented across five chapters. The problem statement, research questions, and working hypothesis for the project are presented in Chapter 1, together with the specific aims and layout of the study. In Chapter 2, a review of the available and relevant literature is given to serve as background for the results of this project and give context for the interpretation thereof. Briefly, Chapter 2 reviews the prevalence of postpartum depression, available treatment options and the possible neurodevelopmental effects of these interventions on the developing brain. This chapter then concludes with a review of available literature, related to the validity of the Flinders sensitive line rat (strain used in the current study) for this research report. Next, the relevant materials and experimental methods used in the current study are described in Chapter 3. Chapter 4 contains the results and findings, together with a detailed description of the statistical methods used, and discussion of the findings against the background of relevant literature. These findings are then summarised in Chapter 5, specifically in response to the various research questions listed in Chapter 1. Based on this discussion, this chapter concludes with a general answer to the overarching research question, posed in Chapter 1. The conclusion is finally used to highlight specific study limitations and direct future research into this topic.

Two addenda are also included in this report to supplement the main body, described above. These include ethical approval certificates from the two relevant Institutions (*Addendum A*), and the Turnitin summary report (*Addendum B*).

To ease reading, a comprehensive reference list is presented at the end of the dissertation (as opposed to after each Chapter).

This dissertation is written in UK English.

## 1.2 Background and problem statement

The first year postpartum is a particularly sensitive period in a women's life, posing significant health risks to both mother and infant (Vernon *et al.*, 2010). Healthcare-associated factors that can be adversely affected during this period include general medical care and costs, breastfeeding, family function and even early brain development in the infant due to suboptimal maternal care (Rafferty *et al.*, 2019). Symptoms of maternal psychological distress can include depression, anxiety, and stress during the postpartum period (Trujillo *et al.*, 2018), which can all contribute to the worsening of the aforementioned factors but also increase the risk to develop other neuropsychiatric disorders, such as obsessive-compulsive disorder (Zambaldi *et al.*, 2009), post-traumatic stress disorder (Grekin & O'Hara, 2014), and anxiety (Tietz *et al.*, 2014). Worldwide, 10 % of pregnant women and 13 % of women who have recently given birth, experience a mental disorder (Centers for disease control and prevention, 2023; Gavin *et al.*, 2005), regardless of familial history of postpartum depression (Sullivan *et al.*, 2000). In South Africa, as much as 37 % of women struggle with depression during the peripartum period – the second highest out of 56 countries (Hahn-Holbrook *et al.*, 2018). Despite early reports indicating postpartum depression prevalence to have increased seven-fold between 2000 and 2015 (Centers for disease control and prevention, 2023), more recent reports point to an even worse prevalence, exacerbated by the recent global Covid-19 pandemic. In fact, the prevalence of maternal psychological stress has increased to such an extent, that as much as 36 % of mothers of children younger than 18 months (Cameron *et al.*, 2020) reported depression and anxiety symptoms – an overall increase of 8 % during the pandemic (from 26 to 34 %) (Wu *et al.*, 2020). Yet, despite these numbers and that universal screening for maternal depression during the perinatal period is recommended by professional bodies, as little as 40 % of women who experience depression during this period, seek medical help (Rafferty *et al.*, 2019).

When left untreated, postpartum depression may lead to suicide, which severely and adversely affects the physical and bio-behavioural development of the new-born child (Frieder *et al.*, 2019). Moreover, untreated, and even undiagnosed postpartum depression can lead to infanticide, which in turn can have devastating effects on the overall wellbeing of the family. In fact, depression is one of the most commonly diagnosed mental disorders in school-aged children (Centers for disease control and prevention, 2020). It is the fourth leading cause of global illness and disability among adolescents (15-19 years of age) and the fifteenth in those younger than 14 years (World Health Organization, 2022). In the United States, almost two million children (aged 3-17 years) have been diagnosed with depression (Centers for disease control and prevention, 2020; Ghandour *et al.*, 2019), with data indicating that 17 % of children (2-8 years), 5 % of 12-year-olds and 17 % of 17-year-olds have at least experienced a major

depressive episode in the year before (Centers for disease control and prevention, 2020; Cree *et al.*, 2018; Selph & McDonagh, 2019). For the South African context, available data suggests that between 13 and 33 % of adolescents struggle with depressive symptoms (Barhafumwa *et al.*, 2016; Nduna *et al.*, 2013). In 2016, an estimated 62 000 adolescents died as a result of self-harm (World Health Organization, 2022), making it the third leading global cause of death in this age group, with the majority (> 90 %) of cases reported in low- or middle-income countries (World Health Organization, 2022).

Regardless, the only currently FDA[1]-approved pharmacological treatment option for mild to severe postpartum depression, is brexanolone (a gamma-aminobutyric acid A receptor positive allosteric modulator) (Payne, 2021). However, it is only available as a continuous intravenous infusion, and may not yet be widely available in all countries, consequently limiting its general use due to practical and financial reasons. Alternatively, the selective reuptake inhibitor (SSRI), fluoxetine, is generally used as a first-line option alternative (Frieder *et al.*, 2019). Fluoxetine crosses the placenta and is expressed in breast milk, which could potentially pose a health risk to the infant (Frieder *et al.*, 2019; Gao *et al.*, 2018). This often results in pregnant and breastfeeding women being sceptical to use antidepressants during the peripartum (including early postpartum) period (Battle *et al.*, 2013; Prady *et al.*, 2016). Importantly, refusal of (pharmacological) antidepressant treatment can negatively influence the development of a child, as postpartum depression can lead to maternal neglect (Dietz *et al.*, 2008), which could set off a range of adverse, and as mentioned, even fatal consequences.

Fluoxetine increases serotonin levels by inhibiting the serotonin transporter, thereby preventing the re-uptake of serotonin into the neuron (DeBattista, 2021). Despite functional polymorphisms affecting the activity of the transporter, SSRIs, such as fluoxetine, inhibit approximately 80 % of the transporter at therapeutic doses (DeBattista, 2021), thereby explaining the clinical popularity of this class of antidepressants. The active metabolite of fluoxetine, norfluoxetine, has an elimination half-life three times greater than that of the parent compound, resulting in prolonged pharmacodynamic effects, even after cessation of treatment (DeBattista, 2021). In fact, monoamine oxidase inhibiting drugs must be avoided for at least four weeks following treatment cessation to avoid serotonin syndrome (DeBattista, 2021). Secondary to the serotonergic-enhancing effects, fluoxetine also affects mitochondrial function. This is of note as mitochondrial (dys)function has recently gained more attention as a promising and novel target to treat depression (Allen *et al.*, 2018; Sharma & Akundi, 2019; Wu *et al.*, 2019). Briefly,

[1] *United States Food and Drug Administration*

mitochondria provides 80 % of cellular needs in the form of adenosine triphosphate (ATP) (Papa *et al.*, 2012) that is necessary for neurotransmission (calcium-regulating properties), neuronal membrane potential maintenance (Cotman & Berchtold, 2002; Mattson *et al.*, 2008; Sheng & Cai, 2012), and neurogenesis (processes that affect neuroplasticity), of which the latter is strongly associated with mitochondria number (Chen *et al.*, 2018). Despite accounting for just 2 % of a person's weight, the human brain requires 20 % of our total glucose and oxygen intake (Manji *et al.*, 2012; Pei & Wallace, 2018; Rolfe & Brown, 1997), with the majority of energy (80 to 90 % of the total brain demand) required for neuronal function (Yu *et al.*, 2018). More specifically, energy is produced by oxidative phosphorylation within the mitochondrial electron transport chain, which, amongst others, produces reactive oxygen species as by-product (Adam-Vizi, 2005). In healthy mitochondria, this reactive oxygen species production is counterbalanced by mitochondrial-produced antioxidant defences (Tse *et al.*, 2016; Turrens, 2003), thereby preventing cellular damage and/or dysfunctional processes. Conversely, when mitochondria function sub-optimally, reactive oxygen species production is increased (Federico *et al.*, 2012; Klinedinst & Regenold, 2015). Without the necessary increase in antioxidant defences, an imbalanced redox status develops, that can lead to cellular damage and apoptosis (Federico *et al.*, 2012). Because increased oxidative stress is associated with various psychological conditions, including depression and anxiety (Lopresti *et al.*, 2014; Miller *et al.*, 2009), it is worth noting that mitochondrial dysfunction has also been linked to several underlying causes of or contributing factors to psychiatric conditions, such as impaired monoaminergic neurotransmission, reduced neuroplasticity, and increased neuro-inflammation (Klinedinst & Regenold, 2015; Mattson *et al.*, 2008; Sharma & Akundi, 2019). It is therefore significant that when reviewing the bio-energetic effects of fluoxetine, both positive and negative effects are observed and is reviewed by Emmerzaal and colleagues (2021). This is of particular interest when considered during the energy dependant neurodevelopmental processes of early-life development (i.e., early postpartum period).

With the above-mentioned considered, together with the fact that fluoxetine and norfluoxetine are expressed in breast milk, and the prolonged effect of the active metabolite, it is understandable that women may be hesitant to start or continue fluoxetine treatment whilst breastfeeding. Clinical data regarding the neurochemical effects of passively administered fluoxetine (i.e., via breast milk) in offspring are largely limited, because of the practical and ethical implications. The knowledge gained from pre-clinical research, is therefore invaluable. Available data suggests mixed results in terms of the effects of passively administered fluoxetine in offspring rodents, specifically during early life development. Studies that did in fact, investigate the effects of fluoxetine delivered via the breast milk in rodent offspring, found that

increased anxiety-like behaviour, impaired hypothalamic-pituitary-adrenal (HPA) axis' negative feedback mechanism, and altered hippocampal immature neurons in a sex dependent manner during adulthood (Gobinath *et al.*, 2016). Furthermore, postpartum fluoxetine also decreased hippocampal markers of neuroplasticity (Boulle *et al.*, 2016), and prevented exercise-induced (Gobinath *et al.*, 2018) neurogenesis in adult offspring. In contrast, Zaccarelli-Magalhães and colleagues (2020) recently reported that although postpartum fluoxetine altered maternal behaviour, it had no effect on juvenile behaviour in the offspring born to these dams. Because the serotonergic system is still developing during the early postpartum period, it is also worth noting that passively administered fluoxetine influences sexual behaviour in adult offspring, again in a sex-dependant manner (Rayen *et al.*, 2013, 2014). Finally, an early clinical study, investigating the absolute concentration of fluoxetine in breast milk, found that the predicted maternal weight-adjusted daily dose of the infant ranges from 2 to 4 % at two weeks and two months of age, respectively (Heikkinen *et al.*, 2003). This was further quantified by Taddio and colleagues (1996), who reported a weight-adjusted dose of 0.17 ± 0.09 mg fluoxetine (equivalent to 10.8 ± 2.2 % of the maternal dose) to be administered to the new-born. However, the exact concentration of this passively administered fluoxetine to reach the developing brain, remains unknown.

As mentioned, the ethical considerations and implications for a clinical study during early-life development is an obvious and serious limitation, making pre-clinical investigations into this topic more important and relevant. To this end, the Flinders sensitive line (FSL) rat is an established, accepted and validated genetic rodent model of depression (Overstreet, 1993; Overstreet & Wegener, 2013), displaying behaviour and neurochemical constructs akin to the clinical condition. That these discrepancies are further successfully reversed by pharmacological (Overstreet & Wegener, 2013) and non-pharmacological antidepressant interventions (Steyn *et al.*, 2018; Steyn *et al.*, 2020), make it a translatable model to investigate the neurodevelopmental effects of passively administered fluoxetine in pre-pubertal offspring.

## 1.3 Research question

With the above-mentioned in mind, pre-clinical investigation into the neurochemical effects of passively administered fluoxetine on the developing brain is required. Moreover, by quantifying the amount of fluoxetine that reaches the developing brain may be of specific importance, specifically in a rodent model of depression (i.e., the FSL rat) with reliable clinical translatability. The current study therefore sets out to answer how much of passively administered fluoxetine (if any) actually reaches the juvenile brain, and what the effects thereof are on serotonin levels and redox state markers?

## 1.4 Study aims and objectives

To accurately answer this research question, various measurable study aims and objectives were set out. Firstly, we aimed to measure fluoxetine (and norfluoxetine) concentrations in the whole brains of 22-day old male and female FSL pups, born to dams treated daily with 10 mg/kg fluoxetine during the postpartum period. Secondary to this, and to inform on the neurodevelopmental consequences of passively administered fluoxetine, serotonin levels, and markers relating to redox state (refer to Table 1-1, below) were measured. Finally, and as context for these results, we also set out to establish baseline strain differences between FSL and FRL pups in terms of the mentioned neurochemical markers, thereby further validating the known depressive-like constructs of the Flinders strain.

**Table 1-1: Study aims and objectives**
*The study aims and objectives summarized here, must be read with Figure 1-1.*

| Study aims | Objectives |
|---|---|
| ***1)*** Quantify the amount of fluoxetine that reaches the pre-pubertal brain in pups via passively (indirect) administration (i.e., via breast milk from treated lactating dams). | Measure the whole brain concentrations of fluoxetine and norfluoxetine in FSL pre-pubertal brain tissue (*Group 2 vs. 3*). |
| ***2)*** Confirm the neurochemical construct differences between the prepubertal FSL and FRL rats. | Measure markers of oxidative stress (GSH[1] and GSSG[2]) and serotonin levels in the pre-pubertal whole brain (*Group 1 vs. 2*). |
| ***3)*** Determine whether sex differences exist in the offspring of any of the above-mentioned objectives. | Compare the above-mentioned parameters between male and female pups via visual inspection and statistical analysis where obvious differences are observed. |

## 1.5 Hypothesis

As a working hypothesis, we expect pre-pubertal FSL rats (regardless of sex) to have lower serotonin levels and increased markers of oxidative stress, relative to healthy FRL controls. Moreover, we hypothesize that passively administered fluoxetine will result in high norfluoxetine/fluoxetine values in the pre-pubertal brain and will reverse the mentioned serotonin and markers of oxidative stress to levels comparable with that of healthy FRL controls.

[1] *reduced glutathione*
[2] *glutathione disulphide (oxidized)*

## 1.6 Study design and layout

The tissue used in the current study was ethically collected and preserved (AnimCare approval number: NWU-00434-21-A5) in a previous study, performed at the North-West University (Oosthuizen, 2022), where approval for analysing these samples in future studies (i.e., the current study) was given. For context, the study layout is summarized in Figure 1-1, below. Briefly, female FSL rats were administered fluoxetine (10 mg/kg/day) or distilled water (as control), subcutaneously, from postpartum day 04 (PPD04) until PPD18. Between PPD19 and 21, postpartum dams underwent a series of behavioural analyses, whereafter they (and the pups) were euthanized, via decapitation on PPD22 (postnatal day 22 for the pups). Whole brains of the pups were removed, snap frozen in liquid nitrogen and stored at -80 °C for neurochemical analyses (*see Chapter 3*). For the FRL group, postpartum FRL dams received vehicle control (i.e., distilled water) during the same intervention period, whereafter they were also euthanized on PND22. As summarized in Figure 1-1, below, a total of 48 offspring samples (1:1 male: female) were used (FRL, *n* = 16; FSL, *n* = 32) in the current study.





**Figure 1-1: Graphical representation of study layout**
*Male (blue) and female (pink) Flinders sensitive and resistant line pups were either exposed to passively administered fluoxetine during early-life development (i.e., PND05 to 18), or not (Groups 1 and 2). Neurochemical analyses of control groups (Groups 1 and 2) will be compared to determine baseline differences of the juvenile brain. Because only depressed patients would be treated with FLX, only FSL rats born to FLX-treated dams will be included and compared to FSL controls. No statistical comparisons between Groups 1 and 3 will be performed.* ***FLX:*** *Fluoxetine (10 mg/kg/day) administered to the dam.* ***FRL:*** *Flinders resistant line.* ***FSL:*** *Flinders sensitive line.* ***PND:*** *Postnatal day.*

## 1.7 Justification of group sizes

The results of an A priori test (*Table 1-2; Means: Difference between two independent means*) are presented below with a suggested 26 animals per group for the analyses at both PND21 confirm strain phenotype (FSL *vs.* FRL).

**Table 1-2: Summary of power analyses performed, justifying the experimental group sizes**

| **Input parameters** | | **Output parameters** | |
|---|---|---|---|
| ***A priori power analysis to determine group sizes*** | | | |
| **Tails** | Two | **Noncentrality parameter ς** | 2.88 |
| **Effect size *d*** | 0.80 (*large*) | **Critical *t*** | 2.01 |
| **α err prob** | 0.05 | **df** | 50 |
| **Power (1 – β prob)** | 0.80 | **Total sample size** | 52 (*26 per group*) |
| **Allocation ratio N2/N1** | 1 | **Actual power** | 0.81 |
| ***Sensitivity analysis, supporting proposed group sizes*** | | | |
| **Tails** | Two | **Noncentrality parameter ς** | 2.90 |
| **α err prob** | 0.05 | **Critical *t*** | 2.04 |
| **Power (1 – β prob)** | 0.80 | **df** | 30 |
| **Sample size group 1** | 16 | **Effect size *d*** | 1.02 (*large*) |
| **Sample size group 2** | 16 | | |

Importantly, recent studies have been able to identify statistical group differences between FSL and FRL rats, using between eight and twelves animals/group (Abildgaard *et al.*, 2011; Hesselberg *et al.*, 2016; Oberholzer *et al.*, 2018; Tillmann & Wegener, 2019), with others (Roets *et al.*, 2023; Whitney *et al.*, 2023b) also confirming the large effect strain difference. Consequently, a Sensitivity analysis (Table 1-2) supports the use of the proposed sixteen animals (8 male and 8 female) per group, with a less than 0.05 difference in required critical *t*-value. Therefore, the proposed sixteen animals per group should be sufficient to identify statistically significant group differences, as well as highlight sex differences, without neglecting research integrity. Importantly, all data sets were first visually inspected for any obvious sex differences, and where evident, separate statistical analyses were used to confirm these apparent differences.

## 1.8 Translatability of the findings and predicted impact

The findings of the current project would not only contribute to the greater neuroscience field but will also be of value to the clinical understanding of the long-term effects of passively administered fluoxetine on the developing brain. Moreover, and to the best of our knowledge,

the concentration of passively administered fluoxetine that reaches the developing brain was quantified for the first time. Overall, if translated to the clinical setting, the findings of this project could inform healthcare providers about the safety of prescribing antidepressants to breastfeeding women and contribute to our limited understanding about the long-term effects of these medications in the developing brain.

## 1.9 Ethical considerations and approval

This study was approved by the AnimCare Ethics Committee of the North-West University (*approval number: NWU-00789-23-A5*; *Addendum A*), where the analyses were performed. Ethical approval was waived by the University of the Witwatersrand (*waiver nr: 25-04-2023-O; Addendum A*). All procedures complied with national legislation that pertains to experimental animal welfare (South African National Standard for the Care and Use of Animals for Scientific Purposes; SANS 10386:2008). The study also complied with the Animal Research: Reporting of *in Vivo* Experiments (ARRIVE) guidelines ensuring that all experimental data are reproducible, transparent, accurate comprehensive and logically ordered to promote well written manuscripts (du Sert *et al.*, 2020). To this end, the ARRIVE Essential 10 points are summarised in Table 1-3, below.

**Table 1-3: ARRIVE Essential 10**

| ARRIVE Essential 10 | Summarized answer / Cross-reference to relevant section |
|---|---|
| **Study design** | Section 1.6 |
| **Sample size** | Sections 1.6 and 1.7 |
| **Inclusion and exclusion criteria** | *Inclusion*: Brain tissue of male and female FSL and FRL pups.<br>*Exclusion*: Any brain tissue with obvious damage. |
| **Randomization** | Because the samples were collected in a previously completed study, the samples are randomly stored (yet accurately labelled). Still, for the available samples, a free online randomization programme (*https://www.randomizer.org/*) was used to select the samples to be analysed. |
| **Blinding** | Not applicable as the samples were collected in a recently completed study (Oosthuizen, 2022). |
| **Outcome measures** | Section 1.6 and Chapter 3 |
| **Statistical methods** | Sections 4.1 |
| **Experimental animals** | Sections 1.6, 2.6 and 3.1 |
| **Experimental procedures** | Chapter 3 |
| **Results** | Chapter 4 |

# CHAPTER 2: LITERATURE REVIEW

This chapter provides a review of the available literature on the topics relevant for the understanding and interpretation of the findings of the current study. To this end, the prevalence of postpartum depression, together with a brief overview of the aetiology of this mental illness is provided. The available treatment options to address to hypothesised aetiology of postpartum depression is then reviewed, with special attention given to fluoxetine. The possible neurodevelopmental effects of these interventions on the developing brain, is then provided, with the Chapter concluding with a brief justification of why the Flinders sensitive line (strain used in the current study) is suitable for the purpose of this research project.

## 2.1 Epidemiology of postpartum depression

Due to improved modern diagnostic tests and general increased social awareness, the prevalence of postpartum depression has increased over recent years (Dadi *et al.*, 2020). However, because of under reporting of diagnosed cases, the actual prevalence remains unknown. According to available data, the global prevalence of postpartum depression, regardless of age, giving birth for the first time (primiparous), or being a single mother, is estimated to be between 14 (Liu *et al.*, 2022) and 17 % (Shorey *et al.*, 2018). Although the prevalence of postpartum depression appears to peak at twelve months postpartum, this is statistically comparable to earlier time points (i.e., 0, 3 and 6 months) (Shorey *et al.*, 2018). Alarmingly, a significant increase in the prevalence of postpartum depression (specifically in low-income countries, such as Brazil, Peru, Thailand, Pakistan and South Africa (Gelaye *et al.*, 2016)) has been observed in more recent years, increasing from 18 % between 2010 and 2012 to 26 % in 2017 (Dadi *et al.*, 2020). This increase was further maintained by the recent global Covid-19 pandemic, with recent meta-analyses estimating between 27 and 34 % of pregnant and lactating women to now suffer from postpartum depression (Chen *et al.*, 2022; Safi-Keykaleh *et al.*, 2022).

This noteworthy impact of Covid-19 on the mental health of new mothers is not unique. In fact, generalized anxiety scores of healthcare workers was also found to be increased during the pandemic (Adibi *et al.*, 2021), thereby highlighting the impact of psychological stress on the development of mood disorders – specifically major depressive disorder. Psychological stressors (as those associated with Covid-19 lockdown regulations) is well-known to accelerate the occurrence of mental health conditions, such as postpartum depression, and is therefore considered a significant risk factor (Çankaya, 2020). Other noteworthy risk factors for postpartum depression, include gestational diabetes, giving birth to boys, having a history of depression (before or during pregnancy), exposure to traumatic events during or prior to pregnancy, and

various socio-demographic factors, such as maternal age employment and marital status, and preterm delivery (Chen *et al.*, 2022; Doyle & Klein, 2020; Liu *et al.*, 2022).

As for the potential mechanisms of these risk factors, the hyperglycaemia and hormonal influences of gestational diabetes may adversely influence the thyroid and stress-axis (i.e., hypothalamic-pituitary-adrenal (HPA) axis) to such an extent, that the response to the sudden and unexpected stress burden of a chronic disease during pregnancy and the postpartum period, triggers depressive symptoms (Liu *et al.*, 2022; Zhang *et al.*, 2005). It must however be noted that in a recent pre-clinical study, Zhao and colleagues (2022) noted that although gestational diabetes induced depressive-like behaviour in postpartum Sprague-Dawley rats, serum corticosterone levels were actually decreased, thereby suggesting that the hyperglycaemic construct, actually inhibited the secretion of cortisol (or corticosterone in rodents) via negative feedback mechanisms. Either way, serotonin concentrations, and the metabolism thereof (tryptophan to serotonin), were decreased in these animals, aligning with the serotonergic dysfunction hypothesis of depression (Fakhoury, 2016; Kambeitz & Howes, 2015). This finding could explain why Clark and colleagues (2019) observed a unidirectional (as opposed to the assumed bi-directional) association of diabetes with depression, stating that depression precedes, but does not follow gestational diabetes. Nevertheless, that they further conclude trauma to increase the risk for both hyperglycaemia and depression (via prolonged HPA activation), links back to the mentioned sudden and unexpected stress impact of being diagnosed with a chronic disease, such as gestational diabetes or pre-eclampsia during pregnancy, of which the latter has been found to not only be a risk factor for depression but is also associated with more severe symptoms (Caropreso *et al.*, 2020).

Intriguingly, although giving birth to a boy has been highlighted as a risk factor for postpartum depression (Mori *et al.*, 2018; Pampaka *et al.*, 2019), the exact neuro-biological mechanism of this association remains to be established. It is therefore important to consider that Hall and Holden (2008) observed that giving birth to a boy was associated with high ACES (appraisals of cognition, emotion and situation) scores, and reliably predicted a tendency to value thoughts negatively – a behavioural trait more strongly associated with postpartum depression than the actual experiencing of a negative thought (Hall & Papageorgiou, 2005).

As for the socio-demographic risk factors, low maternal age, unemployment, being a single parent, pre-term delivery and no or little social support systems, contribute to low parenting competence, which has been shown to be an important mediating factor in the management of postpartum depression (Jones *et al.*, 2019; Martinez-Torteya *et al.*, 2018).

Finally, a history of depression before or during pregnancy significantly increases the risk for postpartum depression. One of the most influential studies supporting this association in postpartum depression is that of Robertson and colleagues (2004), who found that depression during pregnancy and a history of depression prior to pregnancy were two of the strongest predictors of postpartum depression in more than 20 000 postpartum women. In fact, a woman who has experienced a postpartum depressive episode, has between a 30 and 50 % risk of recurrence with subsequent pregnancies (American Psychiatric Association, 2013a). These findings are emphasised by Monroe and colleagues (2014) who reported the significant influence of a positive family history of depression with and without a traumatic life event. According to the American Psychiatric Association (2013b), heritability accounts for 40 % of depressive symptoms, and interestingly, the neuroticism personality trait contributes to a substantial portion of this genetic liability (Puyané *et al.*, 2022). Finally, and according to a recent meta-analysis of genome-wide association studies, although no single nucleotide polymorphism was associated with postpartum depression, significant correlations between postpartum depression, major depressive disorder, bipolar disorder, anxiety disorders, and polycystic ovary syndrome were identified (Guintivano *et al.*, 2023).

## 2.2 Aetiology of postpartum depression

*Although the aetiology of postpartum depression is relevant to the understanding of the approved treatment options and the potential neurochemical effects on the developing brain (discussed later), the details thereof fall beyond the scope of the research question. Therefore, the aetiology of postpartum depression will be briefly discussed here, highlighting the most notable and relevant mechanisms. For a complete discussion, the reader is referred to detailed reviews (Maguire et al., 2020; Ming & Shinn-Yi, 2016; Payne & Maguire, 2019; Zonana & Gorman, 2005) on this topic.*

***

The exact mechanism of postpartum depression remains unknown but is thought to be due to the abrupt hormone withdrawal during the immediate postpartum period (Zonana & Gorman, 2005). Briefly, oestradiol and progesterone levels respectively rise to fifty and ten times the highest menstrual cycle levels during the third trimester of pregnancy, followed by a sudden drop shortly after parturition, and a return to normal levels within the first postpartum week (Bloch *et al.*, 2003). Such significant concentration changes, specifically that of oestrogen, can alter HPA function (Walf & Frye, 2006), which as alluded to earlier, is implicated in the pathophysiology of postpartum depression. To this end, HPA hyperactivity is also observed during pregnancy (Bloch *et al.*, 2003), and although its exact role remains unknown and debated (Meltzer-Brody *et al.*,

2011), elevated corticotropin-releasing hormone (CRH) has been proposed a diagnostic biomarker for postpartum depression (Yim *et al.*, 2009).

Traumatic life events or early-life adversity is known to influence HPA axis function, and to be a sufficient stressor to induce impaired maternal behaviours (Brummelte & Galea, 2010) and depressive-like behaviour in postpartum rodents (Roets *et al.*, 2023; Whitney *et al.*, 2023b). Moreover, antalarmin administration decreases depressive-like behaviour, via its CRH receptor antagonistic properties (Ducottet *et al.*, 2003). This is noteworthy, as the administration of oestradiol has been shown to induce antidepressant-like effects in ovariectomized rats (Bekku & Yoshimura, 2005; Galea *et al.*, 2001), while finasteride, a 5α-reductase inhibitor, induced depressive-like behaviour in female DBA/2J mice (Beckley & Finn, 2007) by preventing progesterone metabolism, and the consequent synthesis of the neurosteroid, allopregnanolone.

Allopregnanolone is of particular importance in postpartum depression, as it is the target of the only approved option for the treatment of postpartum depression (*see Section 2.4.1.1*). It is thought to induce its antidepressant effects by potentiating the gamma aminobutyric acid subtype A ($GABA_A$) receptor (Payne, 2021). The significant involvement of allopregnanolone in the pathophysiology of postpartum depression is supported by reports of decreased levels that correlate with depressive symptoms during the later stages of pregnancy (Hellgren *et al.*, 2014), which are reversed by the administration of the $GABA_A$ modulator, allopregnanolone (Zheng *et al.*, 2019). Moreover, a recent meta-analysis highlighted the significant role of dysfunctional GABAergic neurotransmission in postpartum depression (Guintivano *et al.*, 2023), re-affirming the role of allopregnanolone as a treatment option for postpartum depression.

Finally, and relevant to the current research question, is the role of neurotransmitters in the aetiology of postpartum depression. Although altered GABA, glutamate and dopamine concentrations are also implicated (Payne & Maguire, 2019), the role of serotonin is particularly relevant here. Hyposerotonergia is generally associated with depressive symptoms – an association supported by the therapeutic value of serotonergic-enhancing antidepressants in the treatment of postpartum (Appleby *et al.*, 1997; De Crescenzo *et al.*, 2014; Susser *et al.*, 2016) and non-postpartum (non-puerperal) depression (Hieronymus *et al.*, 2018; Locher *et al.*, 2017). Pre-clinically, decreased serotonergic neurotransmission has also been observed in models of postpartum depression (Qiu *et al.*, 2020; Roets *et al.*, 2023), and confirmed by rodent models of decreased serotonergic receptor expression (Lerch-Haner *et al.*, 2008) and related metabolic pathways (Anderson & Maes, 2013).

Taken together, the aetiology of postpartum depression, as highlighted here, is multifactorial with various neuro-biological pathways and processes (together with their downstream effects)

implicated. Still, the treatment options used clinically, primarily target either GABAergic (brexanolone) or serotonergic neurotransmission (fluoxetine).

## 2.3 Signs and symptoms and the impact on mother-child relationships

The clinical signs and symptoms of postpartum depression are best summarized by the diagnostic criteria of major depressive disorder (non-puerperal depression), as set out in Table 2-1, below.

**Table 2-1: Diagnostic criteria of major depressive disorder, according to the Diagnostic and statistical manual of mental disorders, 5th edition (DSM-V) (adapted from American Psychiatric Association, 2013b)**

| ***five, or more, present most of the day, nearly every day during the same two-week period, and indicated by either the patient or observed by others*)** |
|---|
| Depressed mood. |
| Markedly diminished interest or pleasure in all, or almost all, activities. |
| ***At least one of the two mentioned symptoms above, must be present, together with any of the following:*** |
| Significant weight loss when not dieting or weight gain (more than 5 % of body weight in a month) or decrease/increase in appetite nearly every day. |
| Insomnia or hypersomnia. |
| Psychomotor agitation or retardation. |
| Fatigue or loss of energy. |
| Feelings of worthlessness or excessive inappropriate guilt. |
| Diminished ability to think or concentrate, or indecisiveness. |
| Recurrent thoughts of death (not just the fear of dying), recurrent suicidal ideation. |
| *The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.* |
| *The episode is not attributable to the physiological effects of a substance or to another medical condition.* |
| *The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders.* |
| *There has never been a manic episode or a hypomanic episode.* |

The positive signs and symptoms, listed in Table 2-1 are then used to score the severity of the condition via different approved and validated questionnaires, such as the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Patient Health Questionnaire, or the Edinburgh Postnatal Depression Scale (Mughal *et al.*, 2022; Qaseem *et al.*, 2023), of which the latter is the most popular and also effective in diagnosing postpartum depression (Levis *et al.*, 2020; Park & Kim, 2023). Other postpartum-specific questionnaires

include the Self-Reporting Questionnaire, the Zung Self-Rating Depression Scale and the Postpartum Depression Screening Scale (Mokwena, 2021). Of note, although not separately classified in the DSM-V or by the International Classification of Diseases-10 (ICD-10), the diagnostic criteria for postpartum depression is similar to that described above, with the only exception being that symptom onset (described in Table 2-1) is experienced or observed during the first four (American Psychiatric Association, 2013b) to six (World Health Organization, 2019) weeks after delivery. Importantly, symptom onset can also be during pregnancy (U.S. Food & Drug Administration, 2019). Screening for postpartum depression must therefore be considered and performed up to six months, postpartum (Mughal *et al.*, 2022).

As for the impact of these signs and symptoms (or positive diagnosis) on the mother-infant relationship, it is concerning that the decreased maternal interactions and bonding that is associated with postpartum depression can have serious and fatal consequences. To this end, it is unfortunately worth highlighting the devastating recent murder trial of Lauren Dickason, where these heart breaking consequences were broadcasted to the world (Davis, 2023). Unfortunately, neonaticide and infanticide is often associated with postpartum depression, yet is one of the worst documented causes of death, resulting in systematic data on this topic to be scarce (Spinelli, 2004). Early records do however suggest that an infant under the age of one, is killed daily in the United States, with this number considered to be a significant underestimation of the current global incidence (Overpeck *et al.*, 1998).

Other consequences of postpartum depression, as reviewed and extensively discussed by Mokwena (2021), include difficulty breastfeeding, which can augment the depressive symptoms by fuelling feelings (or perceptions) of being a “failed mother” (Beinschroth, 2020). Increased risk for child malnutrition, which can in turn adversely influence general health and childhood development is also related to postpartum depression, as are compromised emotional attachment to the child, and disrupted social and academic development of the child that increases the risk for the development of mental health conditions (juvenile depression) and impaired cognitive development (Netsi *et al.*, 2018). Alarmingly, these depressive symptoms (and their consequences) can last up to eleven years post-pregnancy, and negatively affect the immediate and broader family (Netsi *et al.*, 2018).

Considered together, accurate screening tools and diagnosis, together with increased awareness into the consequences of postpartum depression cannot be stressed enough. Moreover, appropriate social support structures and effective education can reduce the risk of postpartum depression, and where needed pharmacological treatment strategies can be considered.

## 2.4 Treating postpartum depression

### 2.4.1 General approach to treatment during the postpartum period

According to the most recent treatment guidelines, the American Psychological Association (2019) and College of Physicians (Qaseem *et al.*, 2023) recommend that antidepressant treatment for the general adult population must be initiated on either a psychotherapy strategy (i.e., behavioural with or without cognitive therapy, psychodynamic therapy, and supportive therapy) or a second-generation pharmacological antidepressant (i.e., selective serotonin re-uptake inhibitors; SSRIs). Interestingly, these panels of experts do not appear to prefer a specific class of antidepressants over another and recommend that prescribers must base their decision on the patient-specific nuances and risks for side effects. This approach is mainly due to larger comparative trials (Cipriani *et al.*, 2018), confirming the superiority of all classes of antidepressants over placebo treatment, and highlighting comparable between-class efficacy (Buelt & McQuaid, 2023). As to combining therapeutic interventions, the combination of cognitive behavioural therapy with a second-generation antidepressant (i.e., SSRI) is recommended only in patients with severe, persistent or recurrent symptoms (Buelt & McQuaid, 2023).

Importantly, despite these guidelines being intended for patients diagnosed with major depressive disorder (i.e., non-puerperal depression), the treatment options for women with postpartum depression are similar. Although no official guidelines, such as those mentioned above, exist for postpartum depression, SSRI drugs are generally recommended by clinicians (Dennis & Stewart, 2004). According to meta-analyses, SSRI drugs are superior to placebo controls for the treatment of postpartum depression and are also well tolerated (Brown *et al.*, 2021; Molyneaux *et al.*, 2015). However, the general consensus is that these studies, are generally small and heterogeneous, leading to low certainty of evidence (Brown *et al.*, 2021; Molyneaux *et al.*, 2015).

Because postpartum depressive symptoms can originate during pregnancy, pharmacological treatment can also be initiated during the antenatal period and continued into the postpartum phase. Therefore, studies evaluating the safety and efficacy of these drugs, exclusively in breastfeeding mothers, are scarce. Still, SSRI drugs are recommended while breastfeeding, with sertraline and paroxetine (and not fluoxetine) being the preferred options (Sie *et al.*, 2012). In this regard, perinatal fluoxetine treatment produced the highest proportion of infant plasma levels (22 %) of the antidepressants investigated (Weissman *et al.*, 2004). Intriguingly, although statistically comparable, infants only exposed to postnatal fluoxetine (i.e., via breast milk), had lower plasma levels than those exposed to the drug prenatally (i.e., *in utero*) (2.8 ng/ml *vs*. 7.9 ng/ml) (Weissman *et al.*, 2004). Still, uncertainty regarding the effects of these pharmacological

drugs on the developing new-born, remains unknown and could discourage postpartum women from starting or completing pharmacological treatment regimens (Sachs *et al.*, 2013). Still, the risks of withholding antidepressant treatment during the peripartum period alluded to earlier, remains significant (van den Berg, 2020).

A great deal of uncertainty regarding appropriate and safe treatment strategies for postpartum depression exist. What is however important, is that pharmacological treatment options are not absolutely contraindicated during breastfeeding and can therefore be considered as viable options, as long as the individual drug nuances and risk profile of the patient are considered. Examples of pharmacological considerations, include the elimination half-life of the drug (and its metabolites), lipid solubility, and the bioavailability of the administered ingredient. Chemicals with prolonged half-lives, are more likely to accumulate in breast milk (Kelsey & Ward, 2020; Sachs *et al.*, 2013). High lipid-solubility and bioavailability properties allow the drug to readily cross the placenta and be expressed in breast milk, as well as increases the chances of the drug being absorbed by the infant (Heikkinen *et al.*, 2003; Kelsey & Ward, 2020; Sachs *et al.*, 2013). Other pharmacological characteristics, such as small molecular weight, and low volume of distribution and serum protein binding potential, all facilitate breast milk expression (Kelsey & Ward, 2020; Sachs *et al.*, 2013). Next, significant side effects, such as cardiac arrhythmias, would generally disqualify a treatment option in a breastfeeding mother. Conversely, the discontinuation of breastfeeding is also not advisable (although often considered), as early cessation is positively linked with postpartum depression, whereas exclusive breastfeeding may reduce depressive symptoms (Dias & Figueiredo, 2015; Figueiredo *et al.*, 2014; Watkins *et al.*, 2011). Finally, although the SSRI drugs are recommended by most experts, psychotherapy strategies must be considered as first-line options, where necessary and indicated (i.e., moderate depressive symptoms) (Dominiak *et al.*, 2021).

#### 2.4.1.1 Brexanolone

Brexanolone is the only pharmacological treatment option, indicated for mild to severe postpartum depression, with Sage Therapeutics, Inc. receiving FDA[1]-approval in March 2019 (U.S. Food & Drug Administration, 2019). Currently, it is only available as an intravenous infusion, to be delivered over a total of 60 h, during which close monitoring of the patient required, because of excessive sedation and sudden loss of consciousness, associated with this drug. In fact, this recommendation is included in a Boxed Warning in the prescribing information leaflet (U.S. Food & Drug Administration, 2019).

[1] *United States Food and Drug Administration*

Brexanolone acts as a positive allosteric modulator of the gamma aminobutyric acid subtype A ($GABA_A$) receptor, thereby mimicking the pharmacodynamic effects of allopregnanolone (Walton & Maguire, 2019). As mentioned previously, allopregnanolone levels of women either at risk of, or diagnosed with postpartum depression, have been reported to be decreased, relative to healthy controls (Hellgren *et al.*, 2014). That these levels were also inversely associated with symptom severity (Deligiannidis *et al.*, 2016), support the GABAergic deficit hypothesis of postpartum depression. Furthermore, the HPA axis is also regulated by GABAergic inhibition (Herman *et al.*, 2004), explaining why hypercortisolemia is implicated in the pathophysiology of postpartum depression (Melón *et al.*, 2018), and why brexanolone is effective in treating these neuro-biological shortfalls. Allopregnanolone (and by implication, brexanolone) also acts on the pregnane X receptors – a ligand-activated transcription factor of the nuclear receptors superfamily that regulate CYP3A gene expression, which plays a key role in the body's defence against foreign chemicals (or xenobiotics) (Kliewer *et al.*, 2002) and has been linked with anti-inflammatory properties (Li & Apte, 2015).

As to the efficacy of brexanolone in reversing postpartum depression symptoms, a recent meta-analysis by Zheng and colleagues (2019) found that not only were the antidepressant effects of a single brexanolone infusion, rapid, but these effects also lasted for a week. These effects also appear to be superior to both placebo treatment and SSRI-based regimens (Cooper *et al.*, 2019). The dosage form and administration route of brexanolone, practical and financial restrictions may become evident, and even prevent many women from receiving this treatment option. It is therefore worth highlighting that a cost-effectiveness model analysis, predicted that brexanolone treatment may actually be more affordable than an SSRI-regimen over an eleven year period (Eldar-Lissai *et al.*, 2020). Specifically, the total predicted medical costs for women treated with brexanolone was 7 745 USD (147 307 ZAR[1]) cheaper than an SSRI alternative regimen (65 908 *vs.* 73 653 USD) (Eldar-Lissai *et al.*, 2020).

Finally, brexanolone is expressed in breast milk, with peak levels (125 µg/l) observed between 24 and 48 h of infusion, at maximum dose. These levels, however, drop to below the limit of detection within three days after infusion, and the predicted median weight-adjusted percent of the maternal brexanolone dose, calculated as 0.69 % (Wald *et al.*, 2022). Considered together with the low oral bio-availability of brexanolone, the risk for associated side effects in the infant is reduced, allowing the mother to continue breastfeeding whilst receiving brexanolone treatment (LactMed®, 2023b).

*[1] Calculated on the exchange rate of 18 September 2023 (1 USD = 19.02 ZAR).*

#### 2.4.1.2 Fluoxetine

Fluoxetine is one of the most researched and well-known SSRI drugs available. It prevents the reuptake of serotonin into the neuron, by inhibiting the serotonin transporter, resulting in increased synaptic serotonin levels (DeBattista, 2021). Fluoxetine ($t_{½}$ = 53 h) is highly protein bound (94 %) and hepatically metabolized by *N*-demethylation to its active metabolite, norfluoxetine ($t_{½}$ = 240 h) (Heikkinen *et al.*, 2003; O'Donnell *et al.*, 2018; van den Berg, 2020) which is just as potent as fluoxetine (Heikkinen *et al.*, 2003) and results in prolonged pharmacodynamic effects, even after cessation of treatment (DeBattista, 2021). Because of its moderately potent CYP2D6 inhibiting properties, fluoxetine can decrease the metabolism of other co-administered drugs (i.e., carbamazepine, haloperidol, metoprolol, tamoxifen etc.) that are substrates of this specific pathway (van den Berg, 2020). From a safety perspective, fluoxetine is associated with moderate gastrointestinal (nausea, vomiting and/or diarrhoea) and sexual (inhibited arousal, libido and/or orgasm) side effects, and to a lesser extent agitation, sedation, seizures, weight gain and cardiac-related effects (O'Donnell *et al.*, 2018). However, when compared to other antidepressants, fluoxetine (together with agomelatine, citalopram, escitalopram, sertraline, and vortioxetine) appears to be best tolerated (Cipriani *et al.*, 2018).

Although not FDA[1]-approved, fluoxetine remains one of the most popular drugs to treat postpartum depression (Cipriani *et al.*, 2018). As to infant exposure via passive administration (i.e., via breast milk), data suggest that fluoxetine and norfluoxetine breast milk concentrations peak around 8 to 9 hours after maternal dosing (Hendrick *et al.*, 2001), and are relatively low (yet higher than other SSRIs), thereby reducing the overall risk for drug-induced effects (Gao *et al.*, 2018; Heikkinen *et al.*, 2003). Various studies (Berle *et al.*, 2004; Heikkinen *et al.*, 2003; Kim *et al.*, 2006; Oberlander *et al.*, 2005; Taddio *et al.*, 1996; Weissman *et al.*, 2004) have quantified these concentrations, with the average maternal weight-adjusted dose to which the infant was exposed, across these studies, calculated as 3.96 ± 2.25[2] % [2.07; 5.84[3] %]. To this point, although infant plasma levels of fluoxetine and norfluoxetine have been measured (Epperson *et al.*, 2003; Heikkinen *et al.*, 2003), the exact concentration that reaches the developing brain, remains unknown. Infant adverse effects that are associated with passively administered fluoxetine, include irritability, poor feeding, colic, fussiness, drowsiness and reduced growth (Heikkinen *et al.*, 2003; LactMed®, 2023a). It is however worth noting that no impaired developmental effects were found in these infants, after a one-year follow-up study, supporting

[1] *United States Food and Drug Administration*
[2] *Mean ± standard deviation.*
[3] *Upper and lower limit of the 95 % confidence interval of the mean.*

the continuation of fluoxetine treatment while breastfeeding (LactMed®, 2023a). If, however, the patient or prescriber is concerned, other SSRI drugs (i.e., sertraline) that are less expressed in the breast milk could be considered (Weissman *et al.*, 2004).

## 2.5 Pharmacological treatment options and the impact on the developing infant brain

### 2.5.1 Juvenile brain development

What we know about juvenile brain development, is largely based on pre-clinical (i.e., animal) studies. It is therefore important to keep in mind that the developmental process, although comparable between species, contains species-specific nuances (Dobbing & Sands, 1979; Murrin *et al.*, 2007), such as brain weights of rats at birth being comparable to that of humans at the end of the second trimester (Murrin *et al.*, 2007). To place the developmental process of the rat brain into context with that of its human counterpart, it should be noted that prenatal rodent development occurs over a 21-day gestational period, whereas human development occurs over a period of forty weeks. As previously described by Steyn (2018) and summarized in Figure 2-1, the prenatal developmental period of the rat resembles the first two trimesters of the human process, with the end of the third trimester, being comparable to the development during the first three weeks of a rat pup's life (Kepser & Homberg, 2015). The onset of puberty and start of adolescence in humans is generally accepted to be between twelve and eighteen years of age (Spear, 2007), however, genetics, environment and nutrition may influence the onset thereof. This developmental phase is similar to that of the 35-day old rat (Drzewiecki *et al.*, 2020; Murrin *et al.*, 2007), with adulthood accepted to be from PND60, onwards (Malkesman & Weller, 2009).

In rats, serotonergic neurons are detected first (in the 8 mm embryo), with noradrenergic neurons only detected later (11 mm embryo) (Golden, 1982). By gestational day 10, serotonin transporter mRNA is already detectable (Hansson *et al.*, 1998), with the noradrenergic neurons only starting to differentiate (Lauder & Bloom, 1974; Thomas *et al.*, 1995). Even before this (i.e., gestation day 10), peak levels of tryptophan hydroxylase (the enzyme responsible for serotonin synthesis) is detected (Rho & Storey, 2001), whilst tyrosine hydroxylase, the rate-limiting enzyme responsible for noradrenaline synthesis, is only detectable at gestational day 15 (Chugani *et al.*, 1999; Kato *et al.*, 1982; Murrin *et al.*, 2007). Between gestational days 14 and 17, the majority of brain neuro- and synaptogenesis in most brain regions, take place (Green *et al.*, 1999). As differentiation of the neurons are now already underway, projections of the serotonergic and noradrenergic neurons, reach the cortex by gestational days 17 and 18 (Lauder & Bloom, 1974; Markus & Petit, 1987; Wallace & Lauder, 1983) with the serotonergic neurons already representing adult distributions by gestational day 19 (Aitken & Törk, 1988; Wallace & Lauder, 1983).





**Figure 2-1: Summarized comparison of rodent and human developmental phases**
*A comparison of the different developmental phases of humans and rodents, giving insight into the comparability between species, and aiding the interpretation and translation of pre-clinical (animal) to clinical (human) data (adapted from Kepser & Homberg, 2015; Malkesman & Weller, 2009), and reproduced with the permission of Steyn (2018).*
***PND:** Postnatal day.*

At the time of birth, serotonergic receptor density in the rat brain is at its highest (Daval *et al.*, 1987; Murrin *et al.*, 2007), and includes a functional serotonergic reuptake system (Enjalbert *et al.*, 1978; Nelson *et al.*, 1980; Tissari, 1975). In contrast, noradrenergic receptor expression is only observed from PND01, onwards (Winzer-Serhan & Leslie, 1997; Winzer-Serhan *et al.*, 1996b), with $\alpha_{2A}$ mRNA and low levels of $\alpha_1$ adrenergic receptors being detected around the time of birth (Morris *et al.*, 1980; Winzer-Serhan *et al.*, 1996a).

By PND21, the serotonergic reuptake system is already functioning, whereas detectable levels of noradrenergic reuptake transporters, emerge on PND05, peaking by PND20 (Murrin *et al.*, 2007) when $\alpha_1$ receptor expression mirrors that of adults (Morris *et al.*, 1980). The growth of serotonergic dendrites on PND07 (Lidov & Molliver, 1982; Loizou & Salt, 1970) is so significant, that administration of 8-hydroxy-2-(di-n-propylamino)-tetralin (a 5-$HT_{1A}$ agonist), induces serotonin syndrome-associated behaviour in Sprague-Dawley pups (Darmani & Ahmad, 1999). Two weeks after birth, 5-$HT_2$ receptor densities exceed that of the adult rat, followed by a gradual decline (Roth *et al.*, 1991). That a 5-$HT_{2A/C}$ agonist already induces “wet dog shakes” in pre-pubertal rats (Darmani & Ahmad, 1999), confirms the functionality of these receptors. Also on PND14, a significant increase in striatal tyrosine hydroxylase concentrations is observed, indicating further development of the noradrenergic nervous system (Murrin *et al.*, 2007), and is supported by an increase in noradrenergic neuron firing rates (Nakamura *et al.*, 1987). Noradrenergic receptor densities significantly increase and reach adult levels by PND15 (Happe *et al.*, 2004; Harden *et al.*, 1977; Morris *et al.*, 1980; Pittman *et al.*, 1980; Slotkin *et al.*, 1990) at which time the overall synaptogenesis of the noradrenergic and serotonergic systems are 55 % and 75 %, respectively, completed (Lauder & Bloom, 1975). Interestingly, by PND18 the noradrenergic system in the cerebellum and brainstem reaches maturity (Konkol *et al.*, 1978), however, this is an exception to the general rule that the noradrenergic system matures after the serotonergic one. At three weeks of age, the serotonergic dendrite network is already

comparable to that of the adult rat brain (Dori *et al.*, 1996; Lidov & Molliver, 1982; Loizou & Salt, 1970).

Starting on PND21, serotonin concentrations start to slowly decrease towards adult concentrations (Loizou, 1972; Whitaker-Azmitia, 2005), suggesting maturity. At the same time, a significant increase in tyrosine hydroxylase concentrations in the cortex is observed, emphasising noradrenergic maturation (Murrin *et al.*, 2007). In support, noradrenergic $\alpha_2$ receptor stimulation is at its highest during the fourth postnatal week (Happe *et al.*, 1999). By PND35 the noradrenergic system has reached maturity (Konkol *et al.*, 1978; Loizou & Salt, 1970; Morris *et al.*, 1980; Murrin *et al.*, 2007), although one report suggests noradrenergic synapses to only reach adulthood by PND60 (Markus & Petit, 1987). Regardless, the general consensus is that the serotonergic system matures before the onset of puberty, whilst the adult similarity of the noradrenergic system is only reached with or after pubertal onset (Murrin *et al.*, 2007). This would therefore sensitize the developing infant brain to the neurochemical influence of a serotonergic-enhancing drug, such as fluoxetine.

### 2.5.2 Bio-behavioural effects of early-life exposure to antidepressants

As mentioned previously, both brexanolone and fluoxetine are expressed in the breast milk. However, because of the low oral bioavailability of brexanolone, the risk for associated side effects in the infant appears to be low (LactMed®, 2023b). In contrast, and largely because of the prolonged elimination half-life of norfluoxetine, together with the significant concentrations expressed in the breast milk (Weissman *et al.*, 2004), infant irritability, poor feeding, colic, fussiness, drowsiness and reduced growth are associated with passively administered fluoxetine (Heikkinen *et al.*, 2003; LactMed®, 2023a).

Therefore, due of ethical and practical reasons, the long-term bio-behavioural effects, and mechanisms of neurodevelopmental fluoxetine exposure, remains unknown. Hence, a review of the available pre-clinical data in this regard is invaluable. Importantly, studies exclusively investigating the postnatal exposure to fluoxetine (via breast milk) in offspring are scarce, with the majority of studies generally investigating fluoxetine administration during the extended gestation (including the early postpartum) period.

Maternal (during gestation and lactation) fluoxetine (5 mg/kg/day) did not delay pubertal onset in Wistar rat offspring, as indicated by oestrogen and testosterone plasma concentrations. Moreover, plasma corticosterone levels of pups exposed to fluoxetine during gestation and lactation was also unaffected, as was body weight (Barbosa *et al.*, 2019). Maternal fluoxetine (5 mg/kg/day during gestation and lactation periods) also induced long-lasting neurochemical

effects, with hippocampal methylation of Wistar offspring being altered on PND22 (Toffoli *et al.*, 2014), and lasting into adulthood (Silva *et al.*, 2018). Although anxiety-like behaviour was unaffected by maternal fluoxetine in both juvenile (Toffoli *et al.*, 2014) and adult rats (Houwing *et al.*, 2019; Silva *et al.*, 2018), social behaviour was decreased during adulthood (Silva *et al.*, 2018), while pain sensitivity increased during pre-pubertal development (Toffoli *et al.*, 2014). In terms of depressive-like behaviour and anhedonia, maternal fluoxetine (10 mg/kg/day during gestation and lactation) did not induce any robust alterations in these behavioural parameters of Wistar rats (Houwing *et al.*, 2019) but it must be noted that the differences that were observed by Houwing and colleagues (2019) were dependent on sex and serotonin transporter expression.

Studies that have however investigated the effects of fluoxetine exposure, exclusively during the lactation period, reported less significant findings. For instance, de Andrade Silva and colleagues (2023) observed that Wistar pups, exposed to passively administered fluoxetine (10 mg/kg/day administered to dams) from PND01 to PND21, gained less weight, yet presented with improved hippocampal mitochondrial function ($NAD^+$/NADH)[1] and decreased antioxidant defences (GSH/GSSG). Hippocampal gene expression related to serotonin, and a marker of neuroplasticity (brain-derived neurotrophic factor; BDNF), were however unaffected by passively administered fluoxetine (de Andrade Silva *et al.*, 2023), as was oestrous cyclicity (Ray *et al.*, 2014). Even at escalating doses (1, 10 and 20 mg/kg) of fluoxetine, Zaccarelli-Magalhães and colleagues (2020) observed no behavioural (locomotor and social interactions) effects in Wistar offspring exposed to passively administered fluoxetine, irrespective of dose. In contrast, studies where pups were exposed to acute doses of passively administered fluoxetine, reported increased anxiety-like behaviour later in life together with reduced social behaviour (Olivier *et al.*, 2011).

These effects are somewhat mirrored in clinical studies. For example, infants (younger than six months) that were exposed to fluoxetine via the breast milk (mothers receiving 20 to 40 mg oral fluoxetine, daily), did not show any changes in plasma serotonin levels (Epperson *et al.*, 2003), nor were there any neurological and growth deficits after a one year follow up study in infants exposed to passively administered fluoxetine in relation to controls (Heikkinen *et al.*, 2003). An interesting observation by Hendrick and colleagues (2001), noted that infant plasma fluoxetine and norfluoxetine concentrations were less likely to be detected at daily maternal doses lower than 20 mg. This is noteworthy, as fluoxetine is started at this dose during a period when glomerular filtration rate and metabolic activities are increased, that could result in reduced

[1] *Nicotinamide adenine dinucleotide in its oxidized ($NAD^+$) and reduced (NADH) forms.*

plasma levels (Lee & Burgees, 2020), and explain the general side effects mentioned earlier, that have been reported with fluoxetine during the lactation period. In support of the indicated use of fluoxetine while breastfeeding, Gao and colleagues (2018) found that in a meta-analysis of more than nine million births, available evidence suggests that although a small risk of congenital malformation is associated with fluoxetine (and other SSRIs) during the peripartum period, no significant increase in risk was observed, when the results were restricted to women with psychiatric diagnosis.

## 2.6 The Flinders sensitive line rat as a suitable rodent model

As first described by Russel and Overstreet (1987), the Flinders sensitive line (FSL) was originally bred as a model to be resistant to the organophosphate, diisopropylfluorophosphonate. Instead, a more sensitive rat line was created, displaying several characteristics resembling a depressive-like phenotype. Importantly, the Flinders resistant line (FRL) rat is the appropriate control for the FSL rat and is only more resistant to the organophosphate effects, relative to its FSL counterpart (Russell & Overstreet, 1987). The behavioural deficits, alluded to, displayed by the FSL rat include increased behavioural despair (Abildgaard *et al.*, 2017; Oberholzer *et al.*, 2018; Roets *et al.*, 2023; Tillmann & Wegener, 2019; Uys *et al.*, 2017; Wei *et al.*, 2015), and impaired cognitive function (du Jardin *et al.*, 2016; Oberholzer *et al.*, 2018; Tillmann *et al.*, 2019; Uys *et al.*, 2017), relative to treatment naïve FRL controls. As for the construct validity of this model, the FSL rat presents with serotonergic (Hvilsom *et al.*, 2019; Roets *et al.*, 2023; Whitney *et al.*, 2023b) and noradrenergic (Roets *et al.*, 2023; Whitney *et al.*, 2023b) neurotransmission profiles, akin to the clinical picture of depression. In addition, markers of neuroplasticity are also decreased in this specific strain (Melas *et al.*, 2013; Stiernborg *et al.*, 2022; Wei *et al.*, 2015), whilst oxidative stress (Mohideen *et al.*, 2021; Whitney *et al.*, 2023b) and markers of inflammation (Abildgaard *et al.*, 2017; Wei *et al.*, 2016) are increased. Indications of mitochondrial dysfunction (a cause of increased oxidative stress damage) has also been inferred for this strain (Chen *et al.*, 2013; Whitney *et al.*, 2023a, 2023b) – thereby increasing the validity of it for neuropsychiatric research. Notably, these bio-behavioural deficits are also observed during the early postpartum period (Oosthuizen, 2022; Roets *et al.*, 2023)

In terms of the predictive validity of this strain, the mentioned bio-behaviour deficits are reversed by established pharmacological and non-pharmacological strategies (Kanemaru *et al.*, 2008; Mncube & Harvey, 2022; Overstreet *et al.*, 2004; Steyn *et al.*, 2018; Steyn *et al.*, 2020; Whitney *et al.*, 2023a). Taken together, these characteristics, confirm the FSL rat as an accepted rodent model of depression with strong face (increased behavioural despair behaviour), construct

(altered monoaminergic and redox state) and predictive validity (reversal of bio-behavioural deficits with clinically approved antidepressants).

As to whether the FSL rat is a suitable model for juvenile depression, the FSL rat (irrespective of sex) weighs more than FRL controls, and presents with increased locomotor activity on postnatal day 21 (PND21), that could mimic psychomotor agitation (Whitney *et al.*, 2023b) – two diagnostic signs and symptoms of juvenile depression (American Psychiatric Association, 2013b). At pubertal onset (between PND35 and 43) (Drzewiecki *et al.*, 2020; Murrin *et al.*, 2007), Whitney and colleagues (2023b) reported that male and female FSL rats already displayed behaviour akin to behavioural despair (increased time spent immobile and decreased swimming and struggling). Such behaviour was accompanied by reduced whole brain weight, and increased hippocampal noradrenaline levels, serotonin turnover and oxidative stress – findings that are supported by others (Malkesman & Weller, 2009; Malkesman *et al.*, 2007; Malkesman *et al.*, 2006).

Considered together, the FSL rat is a suitable and appropriate model for the current study, as the face validity characteristics of this strain, can be translated to the human condition, where genetic susceptibility plays a significant role in the mental health of the offspring (2013b). Moreover, that these rats present with a depressive-like phenotype during the postpartum period (Roets *et al.*, 2023), makes it a translatable model to investigate the effects of passively administered fluoxetine in offspring. Finally, that prepubertal, male and female FSL rats also present with serotonergic and oxidative stress deficits, not only makes it a valuable model in terms of genetic predisposition, but also to identify any significant neurochemical alterations, caused by the passively administered fluoxetine.

# CHAPTER 3: MATERIALS AND METHODS FOR NEUROCHEMICAL ANALYSES

This chapter gives a brief description of the analytical methodology used to measure the different neurochemical markers and drug concentrations, as well as data relevant to the validation and reproducibility of the method used. In addition, a brief description of where the samples analysed in this study was sampled from is also given.

## 3.1 Where tissue was sampled from

Animals were bred, supplied by and housed at the DSI/NWU Vivarium (SAVC reg: FR15/13458; SANAS GLP compliance: G0019; AAALAC accreditation file: #1717) of the Pre-Clinical Drug Development Platform of the North-West University. Adult female rats were individually housed with their litter until PPD21 (ethics approval number: NWU-00434-21-A5). No adverse events were reported during the initial study (Oosthuizen, 2022). The analysed tissue was divided into different experimental groups, with an even distribution of male and female samples. All bio-analyses were performed on the liquid chromatography/mass spectrometry (LC-MS) as described below. Importantly, the methods described below used in recent publications (Oosthuizen, 2022; Whitney *et al.*, 2023a, 2023b). To contribute to in-house transparency and validation, as well as interlaboratory reproducibility, a detailed description (including regression line details and specifications of altered analytical settings) of the method used, is also included.

## 3.2 Sample preparation

Whole brain samples were removed from the -80 °C fridge and cut into small pieces, whereafter it was weighed, and 0.5 ml of the Prep solution added to the sample. The Prep solution (0.1 % (*v/v*) formic acid) contained 200 ng/ml escitalopram as internal standard and 1:1 MeOH: Acetonitrile (ACN). This sample and 0.5 ml Prep solution was homogenized by sonication (twice for 12 s, at an amplitude of 14 µ; MSE ultrasonic disintegrator, Nuaillé, FRA), whereafter another 0.5 ml Prep solution was added. The mixture was left on ice for 20 min to complete protein precipitation and then centrifuged at 20 817 rcf for 25 min at 4 ºC. Next, 0.3 ml of the supernatant was transferred to an amber sample vial, that was used for LC-MS analysis. The Ultivo Triple Quadrupole LC-MS System, controlled by the MassHunter software from Agilent Technologies, Inc. (Santa Clara, USA) was used for analyses. Fluoxetine (FLX), norfluoxetine (nFLX), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), and oxidized (GSSG) and reduced (GSH) glutathione concentrations were determined in the whole brain samples.

Results obtained were converted from ng/ml of the injected sample to ng/g of the wet brain tissue weight.

## 3.3 Method validation

### 3.3.1 Standard solutions

Approximately 1 mg of each analyte was dissolved separately in 10 ml of a 10 % MeOH solution in amber volumetric flasks. From the stock solutions of each analyte, a combined serial dilution series consisting of six to seven concentrations were prepared to construct a standard calibration curve and determine the linear range of each metabolite.

### 3.3.2 Internal standard solution

A stock solution of the internal standard, escitalopram, was prepared at a concentration of 200 ng/ml using a solvent mixture of 0.1 % (*v/v*) formic acid and 1:1 MeOH: Acetonitrile (ACN). This working solution was also used for the preparation of the different biological sample matrices and standards.

### 3.3.3 Mobile phase

A gradient mobile phase consisting of (A) 0.1 % formic acid (FA) and LC-MS grade water and (B) 0.1 % formic acid and ACN was prepared. Table 3-1 indicates how the gradient elution of the mobile phase was applied. The 3 min post-time was allowed to reset to the starting condition of mobile phase mixture between (A) and (B).

**Table 3-1: Mobile phase gradient setup**
*The mobile phase was made up of HPLC water, 0.1 % (v/v) formic acid (FA) and 0.1 % acetonitrile (ACN), with a 3-minute post-time running period included.*

| Step | Time (*min*) | A (%) *HPLC water / 0.1 % FA* | B (%) *ACN / 0.1 % FA* |
|---|---|---|---|
| **1** | Start condition 0 | 95.0 | 5.0 |
| **2** | 3.0 | 95.0 | 5.0 |
| **3** | 4.3 | 0.0 | 100.0 |
| **4** | 12.0 | 0.0 | 100.0 |
| **5** | 14.0 | 95.0 | 5.0 |
| **6** | 15.0 | 95.0 | 5.0 |
| **7** | Post-time 3 | 95.0 | 5.0 |

### 3.3.4 Multiple reaction monitoring optimisation

A 1 mg/ml solution of each analyte was used to optimise ionisation and to determine the optimum settings for the detection product ions. Table 3-2 represents the optimum MS settings for each metabolite precursor to qualify and quantify product ions.

**Table 3-2: Optimum instrument settings for the identification and quantification of product ions**
***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***ESC:*** *Escitalopram (internal standard).* ***FLX:*** *Fluoxetine.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***MRM:*** *Multiple reaction monitoring.* ***nFLX:*** *Norfluoxetine.* ***RRT:*** *Relative retention time.*

| **LC instrument settings** | | | | | | | |
|---|---|---|---|---|---|---|---|
| ***Flow rate*** | 0.3 ml/min | | | | | | |
| ***Injection volume*** | 2 µl | | | | | | |
| ***Run time*** | 18 min (15 min plus 3 min post-time) | | | | | | |
| **Mass spectrometer settings** | | | | | | | |
| ***Source parameter*** | Positive value | | | | | | |
| ***Gas temperature*** | 350 °C | | | | | | |
| ***Gas flow*** | 13 l/min | | | | | | |
| ***Nebulizer*** | 60 | | | | | | |
| ***Capillary voltage*** | 4000 V | | | | | | |
| **Analyte setup** | | | | | | | |
| ***Analyte*** | ***Transition (m/z)*** | ***Dwell (ms)*** | ***Fragmentor (V)*** | ***Collision energy (V)*** | ***Polarity*** | ***Scan*** | ***RRT (min)*** |
| ***5-HIAA*** | 192.1 ≥ 145.9 | 100 | 61 | 17 | Positive | MRM | ± 8.446 |
| ***5-HT*** | 177.1 ≥ 160.1 | | 56 | 13 | | | ± 2.196 |
| ***FLX*** | 310.1 ≥ 148.1 | | 51 | 5 | | | ± 9.201 |
| ***GSH*** | 308.1 ≥ 179.0 | | 76 | 9 | | | ± 1.702 |
| ***GSSG*** | 613.2 ≥ 231.0 | | 121 | 37 | | | ± 1.692 |
| ***nFLX*** | 296.1 ≥ 74.0 | | 51 | 169 | | | ± 9.144 |
| ***I.Std (ESC)*** | 325.2 ≥ 108.9 | | 76 | 53 | | | ± 8.963 |

### 3.3.5 Linearity and calibration curve

Linearity was achieved by preparing six to seven standard concentrations of each analyte measured (Table 3-3). Three replicates of each concentration of the standards range were injected onto the LC-MS system to establish linear regression. According to Shabir (2005), the linear regression value ($R^2$) of the calibration curves must not be less than 0.95.

### 3.3.6 Quantification and detection limits

The limits of quantification (LOQ) and detection (LOD) were defined as the minimum concentration where the signal-to-noise ratio was at least 10:1 (LOQ) and 3:1 (LOD) greater than the average background noise of a non-spiked blank sample (a sample only containing the internal standard) at the retention time of each analyte, respectively (Desimoni & Brunetti, 2015; Shrivastava & Gupta, 2011).

### 3.3.7 Precision and accuracy

Four concentrations of each analyte, ranging from low to high, were chosen and three determinations for each concentration were performed to establish precision and accuracy. Precision results were expressed in percentage relative standard deviation (% RSD) from the mean and the acceptability criterion for each concentration level was not to exceed 15 % (Shabir, 2005; U.S. Food & Drug Administration, 2018). The accuracy results for each concentration were determined by comparing the closeness of the mean test concentration result to that of the true concentration value. The accuracy results were expressed as percentage recovery. The acceptability criterion for accuracy was to fall between 90 % to 110 % for each concentration (Shabir, 2005; U.S. Food & Drug Administration, 2018; van de Merbel, 2008).

### 3.3.8 Stability

Stability was determined by injecting the six standard solutions and prepared samples twice onto the LC-MS system over 24 h. The initial injection set was assayed immediately and served as the respective reference values at time zero with a 100 % stability. Samples were left at room temperature in the autosampler tray and reinjected after 24 h. The stability of each analyte was expressed as the mean percentage stability ± standard deviation, at 24 h.

## 3.4 Method validation results

The calibration curves constructed were evaluated by means of interpreting respective linear regression values. Linearity was excellent over the respective calibration ranges (Table 3-3), with the corresponding coefficient of determination ($R^2$) values consistently greater than 0.9999. Moreover, the coefficient of variation for the internal standard was also less than 10 %.

**Table 3-3: Linear regression line equation and coefficient of determination ($R^2$)**
*All calibration curves and linearity were calculated in GraphPad Prism (version 10).* ***% CV:*** *Coefficient of variation.* ***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***ESC:*** *Escitalopram (internal standard).* ***FLX:*** *Fluoxetine.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***LOD:*** *Limit of detection.* ***LOQ:*** *Limit of quantification.* ***nFLX:*** *Norfluoxetine.*

| Analyte | Concentration range | Linear regression equation | $R^2$ | Is slope significantly non-zero? |
|---|---|---|---|---|
| **5-HIAA** | 7.8125; 15.625<br>31.25; 62.5<br>125; 250<br>500 ng/ml | $y$ = 8.01x - 170 | 0.9999 | Yes<br>$p \leq 0.0005$ |
| **5-HT** | | $y$ = 131x - 2334 | | |
| **FLX** | | $y$ = 7.50x - 119 | | |
| **nFLX** | | $y$ = 1.49x - 32.1 | | |
| **GSH** | 1.25; 2.5; 5.0; 10.0; 20.0; 30.0 µg/ml | $y$ = 4446x - 1498 | | |
| **GSSG** | | $y$ = 95.1x - 167 | | |
| ***I.Std (ESC)*** | 200 ng/ml | ***Mean response = 18 402 ± 1 818; % CV = 9.88 %*** | | |

### 3.4.1 Quantification and detection limits

The limits of quantification (LOQ) and detection (LOD) were determined by means of mathematical formula, the signal to noise approach, and also on-column with a 2 µl injection volume for all the analytes (Table 3-4).

**Table 3-4: Limits of quantification and detection results**
***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***FLX:*** *Fluoxetine.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***LOD:*** *Limit of detection.* ***LOQ:*** *Limit of quantification.* ***nFLX:*** *Norfluoxetine.*

| Analyte | Calculation approach | | Signal to noise approach | |
|---|---|---|---|---|
| | ***LOQ*** | ***LOD*** | ***LOQ*** | ***LOD*** |
| **5-HIAA (*ng/ml*)** | 115.03 | 37.96 | 7.8125 | 3.90625 |
| **5-HT (*ng/ml*)** | 93.65 | 30.90 | 7.8125 | 3.90625 |
| **FLX (*ng/ml*)** | 100.49 | 33.16 | 15.625 | 7.8125 |
| **nFLX (*ng/ml*)** | 99.75 | 32.92 | 15.625 | 7.8125 |
| **GSH (*µg/ml*)** | 1.51 | 0.49 | 0.3125 | 0.3125 |
| **GSSG (*µg/ml*)** | 3.43 | 1.13 | 0.625 | 0.625 |

### 3.4.2 Precision and accuracy

The precision and accuracy results of the four tested concentrations of each analyte are provided in Table 3-5. Both precision and accuracy results were within the acceptable criteria ranges set by the method validation parameters. For all four concentrations of the respective analytes, the percentage RSD (relative standard deviation) for both intra- and inter-sample precision was below the required 15 % (*Intra* = 5.21 ± 3.51 % [3.7; 6.7 %]; *Inter* = 4.96 ± 4.32[1] % [3.1; 6.8[2] %]). Inter-sample values were unfortunately not calculated and must be determined in prospective studies using this method. The accuracy of all concentration levels for all the analytes tested was between 84 % and 109 % (mean value = 94.4 ± 5.69[3] % [94.0; 98.8[4] %]).

[1] *Mean ± standard deviation.*
[2] *Upper and lower values of the 95 % confidence interval of the mean.*
[3] *Mean ± standard deviation.*
[4] *Upper and lower values of the 95 % confidence interval of the mean.*

**Table 3-5: Accuracy and precision results**
***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***FLX:*** *Fluoxetine.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***nFLX:*** *Norfluoxetine.* ***RSD:*** *Relative standard deviation.*

| [Analyte] | Intra-sample (*n* = 3) | | | [Analyte] | Inter-sample (*n* = 3) | | |
|---|---|---|---|---|---|---|---|
| | ***Measured c*** | ***Precision (% RSD)*** | ***Accuracy (%)*** | | ***Measured c*** | ***Precision (% RSD)*** | ***Accuracy (%)*** |
| **5-HIAA (*ng/ml*)** | | | | | | | |
| ***7.8125*** | *6.59* | *11.78* | 84.32 | ***7.8125*** | *6.19* | *14.35* | 79.35 |
| ***15.625*** | *15.13* | *2.56* | 96.84 | ***15.625*** | *14.67* | *0.76* | 93.94 |
| ***31.25*** | *30.40* | *9.30* | 97.29 | ***31.25*** | *29.39* | *6.49* | 90.87 |
| ***62.5*** | *63.93* | *8.07* | 102.28 | ***62.5*** | *65.03* | *9.14* | 104.05 |
| **5-HT (*ng/ml*)** | | | | | | | |
| ***7.8125*** | *6.68* | *2.40* | 85.62 | ***7.8125*** | *6.37* | *2.62* | 81.65 |
| ***15.625*** | *15.16* | *0.86* | 97.03 | ***15.625*** | *14.91* | *1.34* | 95.46 |
| ***31.25*** | *32.73* | *2.85* | 104.74 | ***31.25*** | *33.10* | *3.56* | 105.94 |
| ***62.5*** | *67.95* | *1.09* | 108.72 | ***62.5*** | *70.38* | *2.27* | 112.62 |
| **FLX (*ng/ml*)** | | | | | | | |
| ***7.8125*** | *7.32* | *6.92* | 93.78 | ***7.8125*** | *6.93* | *4.87* | 88.78 |
| ***15.625*** | *15.43* | *5.22* | 98.75 | ***15.625*** | *14.99* | *5.01* | 95.94 |
| ***31.25*** | *29.83* | *4.42* | 95.45 | ***31.25*** | *26.99* | *2.73* | 86.39 |
| ***62.5*** | *60.09* | *1.34* | 96.15 | ***62.5*** | *56.58* | *2.61* | 90.52 |
| **nFLX (*ng/ml*)** | | | | | | | |
| ***7.8125*** | *7.31* | *9.58* | 93.57 | ***7.8125*** | *7.71* | *15.73* | 98.75 |
| ***15.625*** | *15.80* | *4.43* | 101.18 | ***15.625*** | *14.59* | *4.80* | 93.41 |
| ***31.25*** | *30.78* | *7.30* | 98.50 | ***31.25*** | *28.35* | *14.39* | 90.73 |
| ***62.5*** | *61.54* | *4.55* | 98.46 | ***62.5*** | *58.30* | *4.33* | 93.28 |
| **GSH (*µg/ml*)** | | | | | | | |
| ***1.25*** | *1.22* | *1.04* | 98.04 | ***1.25*** | *1.20* | *2.98* | 96.51 |
| ***2.5*** | *2.41* | *6.44* | 96.41 | ***2.5*** | *2.45* | *2.67* | 96.85 |
| ***5.0*** | *4.96* | *4.42* | 99.33 | ***5.0*** | *4.90* | *1.47* | 98.02 |
| ***10.0*** | *9.64* | *4.35* | 96.42 | ***10.0*** | *9.44* | *1.27* | 94.43 |
| **GSSG (*µg/ml*)** | | | | | | | |
| ***1.25*** | *1.19* | *2.00* | 95.82 | ***1.25*** | *1.12* | *2.57* | 89.55 |
| ***2.5*** | *2.10* | *2.74* | 84.06 | ***2.5*** | *2.09* | *2.32* | 83.70 |
| ***5.0*** | *4.90* | *13.81* | 98.01 | ***5.0*** | *4.59* | *7.74* | 91.84 |
| ***10.0*** | *9.38* | *7.52* | 93.83 | ***10.0*** | *8.87* | *2.89* | 88.76 |

### 3.4.3 Percentage recovery and stability

The mean absolute recovery for each analyte measured in triplicate for all four tested concentrations was constantly above 90 % with the mean recovery indicated in Table 3-6. All the analytes were found to be stable within a 48-h period in the autosampler at room temperature.

**Table 3-6: Percentage recovery results**

*Where applicable data are presented as mean ± standard deviation and range of results.* ***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***FLX:*** *Fluoxetine.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***nFLX:*** *Norfluoxetine.*

| Analyte | Concentration | Recovery (%) (*n* = 3) | |
|---|---|---|---|
| | | mean ± SD | Range |
| **5-HIAA (*ng/ml*)** | 7.8125 | 90.00 ± 13.33 | 76.7 – 103.3 |
| | 31.25 | 89.09 ± 8.67 | 82.1 – 98.8 |
| | 125 | 98.89 ± 3.14 | 95.3 – 101.2 |
| **5-HT (*ng/ml*)** | 7.8125 | 100.58 ± 2.51 | 98.3 – 103.3 |
| | 31.25 | 94.15 ± 2.71 | 91.3 – 96.7 |
| | 125 | 98.05 ± 1.45 | 96.4 – 98.9 |
| **FLX (*ng/ml*)** | 7.8125 | 103.45 ± 11.95 | 89.7 – 110.3 |
| | 31.25 | 101.47 ± 4.98 | 96.7 – 106.6 |
| | 125 | 96.71 ± 2.91 | 93.4 – 98.7 |
| **nFLX (*ng/ml*)** | 7.8125 | 83.33 ± 7.22 | 75.0 – 87.5 |
| | 31.25 | 89.66 ± 7.65 | 86.2 – 96.6 |
| | 125 | 99.69 ± 6.57 | 95.3 – 103.8 |
| **GSH (*µg/ml*)** | 1.25 | 97.51 ± 1.10 | 96.3 – 98.3 |
| | 5.0 | 99.83 ± 4.50 | 94.7 – 103.0 |
| | 10.0 | 100.48 ± 4.65 | 97.6 – 105.8 |
| **GSSG (*µg/ml*)** | 1.25 | 95.83 ± 3.61 | 93.8 – 100.0 |
| | 5.0 | 92.80 ± 14.48 | 81.7 – 109.2 |
| | 10.0 | 100.12 ± 2.59 | 98.2 – 103.1 |

# CHAPTER 4: RESULTS AND DISCUSSION

This chapter provides a detailed description of the statistical methods used to analyse the data (Section 4.1), followed by the specific results of each of the analysed parameters (Section 4.2). In Section 4.3, these results are compared against available literature, and discussed against the background of the working hypothesis, stated in Chapter 1.

## 4.1 Statistical analyses

Statistical analyses were performed in IBM® SPSS® Statistics (version 28.0), assisted by Laerd Statistics® (https://statistics.laerd.com). All graphical representations were prepared in GraphPad Prism® (version 10) with the initial power analysis performed in G*Power (version 3; Universität Kiel, GER; Section 1.7). Effect magnitude calculations were done in Exploratory Software for Confidence Intervals (Cumming, 2013) and ® SPSS® Statistics.

All data sets were first screened for outliers (Grubbs' test with $\alpha = 0.05$ accepted as significant) and tested for normality of distribution and homogeneity of variances, with the Shapiro-Wilk and Levene's tests, respectively (only instances where data sets violated these assumptions are reported in figure or table legends). Regardless of the latter, independent *t*-tests with Welch correction (or Mann-Whitney *U*-test) were used for all analyses. A *p*-value < 0.05 (two-tailed) was accepted as significant, while $p \leq 0.07$ was considered an indication of a strong trend. All statistical analyses were however followed up with effect magnitude calculations (American Psychological Association, 2009; Cumming *et al.*, 2007) to support and inform statistical results. Specifically, the unbiased Cohen's *d* ($d_{unb}$) value (Cumming, 2013) was used (and reported with a 95 % confidence interval of the effect magnitude (du Sert *et al.*, 2020)), and considered large when $d_{unb} \geq 0.8$. To determine whether there were statistically significant sex differences for the parameters measured, an ordinary two-way ANOVA (analysis of variance) was performed, with sex and strain (or treatment) set as influencing factors. Here, only the main effect of sex is however reported to confirm visual inspection of sex distribution. For these analyses, the partial eta squared ($\eta_p^2$) was used as effect magnitude indicator, with $\eta_p^2 \geq 0.14$ (Ellis, 2010) accepted as a large effect. All descriptive statistics are reported as mean ± standard deviation, unless stated otherwise (indicated as footnotes).

## 4.2 Results

As summarized in Table 4-1, below, there were no statistically significant differences in terms of brain weight between the different experimental groups (*Strain effect*: $t_{25.0} = 1.27$, $p = 0.21$, $d_{unb}$

= 0.4 [-0.3; 1.1] and *FLX[1] effect*: $t_{30.0}$ = 0.71, $p$ = 0.48, $d_{unb}$ = 0.2 [-0.4; 0.9]). Importantly, because these samples were collected in another study (Oosthuizen, 2022), the pups were unfortunately not weighed prior to being euthanised and therefore, the brain weight cannot be expressed as a percentage of body weight. Regardless, these brain weights were used to calculate the concentrations of the various neurochemical markers, reported here.

**Table 4-1: Descriptive statistics of the brain weight data of the different experimental groups**
*Whole brain weight of male and female FSL and FRL pups on PND22.* ***95 % CI:*** *95 % confidence interval.* ***FRL:*** *Flinders resistant line.* ***FSL:*** *Flinders sensitive line.* ***PND:*** *Postnatal day.* ***SD:*** *Standard deviation.*

| Strain | Passively administered fluoxetine | Brain weight (*mg*) *mean ± SD (n)* | *95 % CI* | *Range* |
|---|---|---|---|---|
| **FRL** | ***no*** | 993.7 ± 50.5 (*16*) | 966.8 – 1021.0 mg | 933.3 – 1086.0 mg |
| **FSL** | ***no*** | 1024.0 ± 81.5 (*16*) | 980.8 – 1068.0 mg | 823.8 – 1158.0 mg |
| | ***yes*** | 1045.0 ± 80.6 (*16*) | 1002.0 – 1088.0 mg | 911.0 – 1172.0 mg |

### 4.2.1 Whole brain fluoxetine and norfluoxetine concentrations

Whole brain fluoxetine was undetectable (below the limit of detection) by the methods used in the current study. However, norfluoxetine, the active metabolite of fluoxetine, was successfully quantified, with passively administered fluoxetine during pre-pubertal development (from postnatal day 05 to 18) resulting in 41.28 ± 6.47 ng/g norfluoxetine in the whole brain of juvenile (PND21) FSL rats. Of note, this concentration was also comparable between male[2] and female pups ($t_{8.82}$ = 0.73, $p$ = 0.48, $d_{unb}$ = 0.4 [-0.6; 1.4]).

Moreover, when expressing the amount norfluoxetine to have reached the brain of pre-pubertal pups, as a percentage of the mean dose administered to the postpartum FSL dam, our findings suggest that 0.0014 ± 0.003 % of the mean daily fluoxetine dose[3] reached the brain of the FSL pups in the form of norfluoxetine.

[1] *Fluoxetine*
[2] *One sample was excluded from the male group because of result being below the limit of detection.*
[3] *As described in Section 1.6, postpartum FSL dams received fluoxetine (10 mg/kg/day) via subcutaneous injections. Based on the data of Oosthuizen (2022), the average daily weight of these dams was 293.5 ± 21.1 g over the treatment period (i.e., PPD05 to 18). Using this daily average, the mean fluoxetine dose administered over the fourteen-day intervention period was 2.94 ± 0.21 mg/day, which was in turn used to calculate the percentage of norfluoxetine to have reached the offspring brain.*

### 4.2.2 Serotonin and 5-hydroxyindoleacetic acid

As summarized in Table 4-2, below, there were no statistically significant differences between FSL and FRL controls, regardless of sex, for either serotonin ($t_{27.7}$ = 0.473, $p$ = 0.64, $d_{unb}$ = 0.2 [-0.5; 0.9]) or 5-hydroxyindoleacetic acid ($t_{23.8}$ = 1.23, $p$ = 0.23, $d_{unb}$ = 0.3 [-0.3; 1.1]). Similarly, passively administered fluoxetine did not alter whole brain serotonin ($t_{27.1}$ = 0.48, $p$ = 0.53, $d_{unb}$ = 0.2 [-0.5; 0.9]) or its metabolite ($t_{20.0}$ = 0.11, $p$ = 0.92, $d_{unb}$ = 0.04 [-0.7; 0.7]) of FSL rats (irrespective of sex).

In support of the above-mentioned results, sex had no statistically significant impact on whole brain serotonin ($F_{1, 28}$ = 0.23, $p$ = 0.42, $\eta_p^2$ = 0.02) and 5-hydroxyindoleacetic acid ($F_{1, 28}$ = 0.05, $p$ = 0.82, $\eta_p^2$ = 0.002) in FSL and FRL rats. Similarly, passively administered fluoxetine had similar effects on whole brain serotonin ($F_{1, 28}$ = 0.09, $p$ = 0.77, $\eta_p^2$ = 0.003) and its metabolite ($F_{1, 28}$ = 0.02, $p$ = 0.90, $\eta_p^2$ = 0.001) in male and female FSL rats.

**Table 4-2: Summary of serotonergic markers in the whole brain of FSL and FRL juvenile rats**
*The 5-HT and 5-HIAA values were used to calculate the 5-HIAA/5-HT ratio, reported in the text.* ***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***FRL:*** *Flinders resistant line.* ***FSL:*** *Flinders sensitive line.* ***SD:*** *Standard deviation.*

| Strain | Passively administered fluoxetine | 5-HIAA (*ng/g*) *mean ± SD (n)* | 5-HT (*ng/g*) *mean ± SD (n)* | 5-HIAA/5-HT *mean ± SD (n)* |
|---|---|---|---|---|
| **FRL** | ***no*** | 105.2 ± 16.4 (*16*) | 33.28 ± 5.40 (*16*) | 3.22 ± 0.64 (*16*) |
| **FSL** | ***no*** | 95.06 ± 28.81 (*16*) | 34.07 ± 4.01 (*16*) | 2.80 ± 0.82 (*16*) |
| | ***yes*** | 95.88 ± 11.90 (*16*) | 34.67 ± 2.86 (*16*) | 2.77 ± 0.27 (*16*) |

As before, sex had no statistically significant influence on the serotonin turnover, either between FSL and FRL pups ($F_{1, 28}$ = 0.09, $p$ = 0.77, $\eta_p^2$ = 0.003), or between FLX and CRL FSL offspring ($F_{1, 28}$ = 0.08, $p$ = 0.78, $\eta_p^2$ = 0.003).

Serotonin turnover (5-HIAA/5-HT) was also comparable between strains (Figure 4-1; $t_{28.3}$ = 1.61, $p$ = 0.12, $d_{unb}$ = 0.6 [-0.1; 1.3]), with no statistically significant influence of passively administered fluoxetine in the whole brain of juvenile FSL rats (Figure 4-1; $t_{18.2}$ = 0.18, $p$ = 0.86, $d_{unb}$ = 0.06 [-0.6; 0.8]). Interestingly, the coefficient of variance for the pups that received fluoxetine via breast milk was lower than those that did not (9.74 % *vs*. 29.3 %).





**Figure 4-1: Whole brain serotonin turnover of FSL and FRL rats**
*Data points represent the mean ± 95% CI, with male and female indicated in blue and purple, respectively. Statistical results are reported in the text.* ***5-HIAA:*** *5-hydroxyindoleacetic acid.* ***5-HT:*** *5-hydroxytryptamine.* ***CRL:*** *Control (distilled water).* ***FLX:*** *Fluoxetine (passively administered via breast milk).* ***FRL:*** *Flinders resistant line.* ***FSL:*** *Flinders sensitive line.*

### 4.2.3 Redox markers

As summarized in Table 4-3, there were statistically significant differences between FSL and FRL controls, regardless of sex, for both GSH ($U$ = 54, $z$ = -2.79, $p$ = 0.004, $d_{unb}$ = 1.0 [0.2; 1.7]) and GSSG ($U$ = 234, $z$ = 4.00, $p \leq 0.0005$, $d_{unb}$ = 1.8 [1.0; 2.7]). In contrast, passively administered fluoxetine decreased whole brain GSH ($U$ = 187, $z$ = -2.9, $p$ = 0.003, $d_{unb}$ = 1.8 [1.0; 2.7]), without affecting GSSG concentrations ($U$ = 283, $z$ = 0.72, $p$ = 0.49, $d_{unb}$ = 0.4 [-0.3; 1.1]).

There were, however, no sex differences between FSL and FRL rats for either whole brain GSH ($F_{1, 28}$ = 2.31, $p$ = 0.14, $\eta_p^2$ = 0.08) or GSSG ($F_{1, 28}$ = 1.87, $p$ = 0.18, $\eta_p^2$ = 0.06) concentrations. Similarly, there were no statistically significant sex differences for FSL rats exposed to passively administered fluoxetine (*GSH*: $F_{1, 28}$ = 1.55, $p$ = 0.22, $\eta_p^2$ = 0.05; and *GSSG*: $F_{1, 28}$ = 1.69, $p$ = 0.20, $\eta_p^2$ = 0.06).

**Table 4-3: Summary of redox markers in the whole brain of FSL and FRL juvenile rats**
*The GSH and GSSG values were used to calculate the GSH/GSSG ratio, reported in the text.* ***FRL:*** *Flinders resistant line.* [a)] *Outlier identified but not removed from analysis.* [b)] *Data not normally distributed.* [c)] *When excluding the identified outlier, the fluoxetine effect narrowly misses statistical significance ($t_{28.6}$ = 2.03, p = 0.05, $d_{unb}$ = 0.7 [-0.008; 1.4]).* ***FSL:*** *Flinders sensitive line.* ***GSH:*** *Glutathione.* ***GSSG:*** *Glutathione disulphide.* ***SD:*** *Standard deviation.*

| Strain | Passively administered fluoxetine | GSH (*µg/g*) *mean ± SD (n)* | GSSG (*µg/g*) *mean ± SD (n)* | GSH/GSSG *mean ± SD (n)* |
|---|---|---|---|---|
| **FRL** | ***no*** | 32.62 ± 7.07 (*16*) | 163.3 ± 77.44 (*16*) | 0.25 ± 0.12 (*16*) |
| **FSL** | ***no*** | 25.54 ± 5.92 (*16*) | 338.8 ± 106.7 (*16*) | 0.08 ± 0.04 (*16*[a,b,c]) |
| | ***yes*** | 18.22 ± 6.75 (*16*) | 384.1 ± 141.0 (*16*) | 0.05 ± 0.03 (*16*) |

The GSH/GSSG ratio was higher in juvenile FRL rats, compared to age matched FSL controls (Figure 4-2; $U$ = 24, $z$ = -3.92, $p \leq 0.0005$, $d_{unb}$ = 1.8 [1.0; 2.7]). Interestingly, passively administered fluoxetine further decreased the GSH/GSSG ratio in juvenile FSL rats (Figure 4-2; $U$ = 74, $z$ = -2.04, $p$ = 0.04, $d_{unb}$ = 0.8 [0.05; 1.5]). Again, these findings were independent of sex (*Strain*: $F_{1, 28}$ = 1.57, $p$ = 0.22, $\eta_p^2$ = 0.05; and *Treatment*: $F_{1, 28}$ = 0.25, $p$ = 0.08, $\eta_p^2$ = 0.11).





**Figure 4-2: Whole brain redox status of FSL and FRL rats**
*Data points represent the mean ± 95% CI, with male and female indicated in blue and purple, respectively. Statistical results are reported in the text, with **** p ≤ 0.0005, ^ p < 0.05, and d ≥ 0.8 (significant large effect) vs. indicated group.* ***GSH:*** *Glutathione.* ***GSSG:*** *glutathione disulphide.* ***CRL:*** *Control (distilled water).* ***FLX:*** *Fluoxetine (passively administered via breast milk).* ***FRL:*** *Flinders resistant line.* ***FSL:*** *Flinders sensitive line.*

## 4.3 Discussion

### 4.3.1 Model validation (FSL *vs.* FRL)

As described earlier (Section 2.6), the FSL rat is an approved, accepted, and validated model of depression. However, evidence for the depressive-like phenotype of this strain is mainly based on observations during adulthood, with less information available during the juvenile developmental period. The Malkesman group is leading the neuro-behavioural field in this regard, reporting on the usefulness of the FSL rat as a suitable model for childhood depression. Summarized, hypocortisolism (Braw *et al.*, 2006; Malkesman *et al.*, 2006), monoaminergic deficiencies (Malkesman *et al.*, 2008; Malkesman *et al.*, 2007; Whitney *et al.*, 2023b) and altered hippocampal redox status (Whitney *et al.*, 2023b), together with reduced brain (Whitney *et al.*, 2023b) and body weight (Malkesman *et al.*, 2006) have all been reported in juvenile FSL rats. These neurochemical differences were observed in the presence of increased behavioural despair (Whitney *et al.*, 2023b) and altered social behaviour. Interestingly, the increased social behaviour, displayed by these animals, could be a sign of aggression (Malkesman *et al.*, 2006), especially considering the association between antisocial behaviour and low cortisol levels observed in depressed children (Miller *et al.*, 2007). Finally, pre-pubertal FSL rats do not display signs of increased anxiety-like behaviour (Whitney *et al.*, 2023b) or anhedonia (Malkesman *et al.*, 2005), which is in line with the original description of the FSL rat as "*a model of depression without comorbid anxiety*" (Overstreet & Wegener, 2013).

Within this context, the current findings support the validity of the FSL rat as a suitable model for childhood depression (*see results reported in Section 4.2*). Although we previously reported increased serotonin turnover in PND38 male and female FSL rats (Whitney *et al.*, 2023b), the current findings identified no strain differences (Figure 4-1). This discrepancy could possibly be explained by the different brain areas analysed (hippocampus *vs*. whole brain), which prospective studies must consider. Still, Malkesman and colleagues (2007) also observed no strain differences between FSL and Sprague-Dawley juvenile controls in terms of serotonin turnover in the nucleus accumbens, yet did identify age-dependent differences. It could therefore be that monoaminergic changes occur over time that may (or may not) influence the behavioural profile of these animals. This hypothesis deserves further investigation, as the exact role of serotonin in the pathophysiology of depression has been questioned (Andrews *et al.*, 2015) and recently become a topic of debate (Jauhar *et al.*, 2023; Moncrieff *et al.*, 2022). Studies comparing the neurodevelopmental depressive-like phenotype of the Flinders line strain would be valuable to not only confirm the mentioned neurochemical differences, but also determine whether depressive-like behaviour changes over time.

Glutathione (GSH) is a potent intra- and extracellular antioxidant that when oxidised to GSSG (glutathione disulphide), reduces antioxidant protection. The concentration of GSH, relative to GSSG (GSH/GSSG) is therefore a valuable biomarker of cellular redox state, with lower levels indicating decreased antioxidant defences and consequently infers increased oxidative stress (Zitka *et al.*, 2012). In line with our previous findings (Whitney *et al.*, 2023b), the current results suggest that pre-pubertal FSL rats have reduced antioxidant defences (Figure 4-2), which may have contributed to the earlier mentioned, brain atrophy. This is valuable, as the immune-inflammatory and nitro-oxidative pathway is activated in patients with suicidal ideation and attempts (Vasupanrajit *et al.*, 2022), and correlates with our previous findings, suggesting PND21 male and female FSL rats to display psychomotor agitation (Whitney *et al.*, 2023b) – a characteristic of childhood depression (American Psychiatric Association, 2013b).

Our findings support the neurochemical construct of the FSL rat as a suitable model for childhood depression, presenting with decreased whole brain antioxidant defences. Further studies are however needed to validate the face validity (behavioural deficits) of this strain at such a young age. Based on these findings, the FSL rat is a suitable model to investigate the neurochemical effects of passively administered fluoxetine in the developing brain, despite having comparable whole brain serotonin concentrations on PND21.

### 4.3.2 The fluoxetine effect

Being a serotonergic-enhancing drug, fluoxetine could potentially alter serotonergic function in the developing brain of offspring exposed to it via breast milk. This is supported by the clinical response to serotonergic (and not noradrenergic) enhancing antidepressants in children and adolescents (Cipriani *et al.*, 2016; Murrin *et al.*, 2007). Moreover, that the serotonergic pathway matures before the adrenergic one, could further sensitize the developing brain to the effects of increased serotonin (Andersen, 2003; Andersen & Navalta, 2011). Consequently, we investigated the effects of passively administered fluoxetine in pre-pubertal FSL rats, specifically in terms of serotonin and oxidative stress, reported to be altered or compromised during juvenile development (Malkesman *et al.*, 2007; Whitney *et al.*, 2023b).

First, we were able to quantify whole brain fluoxetine and norfluoxetine levels, which to the best of our knowledge is novel. To this end, fluoxetine was undetectable, whilst the mean norfluoxetine concentration was quantified as 41.28 ± 6.47 ng/g in male and female FSL pups (Section 4.2.1). Our findings are supported by others (Epperson *et al.*, 2003; Heikkinen *et al.*, 2003; Hendrick *et al.*, 2001) who observed increased plasma norfluoxetine/fluoxetine ratios in infants exposed to passively administered fluoxetine. The translatability of our findings are

further emphasized by Caccia and colleagues (1990) who investigated the pharmacokinetics of a single fluoxetine dose to a rat, and found that at lower doses (5 to 10 mg/kg; the latter being administered to the lactating dams of the current study), the kinetic profile of fluoxetine is generally comparable between rats and humans. Still, the species-specific nuances that must be noted is that the elimination time of fluoxetine and norfluoxetine is shorter in rats, than in humans (FLX: 4 to 7 h *vs.* 1 to 4 days; nFLX: 15 h *vs.* 7 days), and fluoxetine may follow non-linear kinetics from 10 mg/kg, and higher. In rats, peak plasma concentration of a single oral fluoxetine dose (5 and 10 mg/kg) is reached after 3.3 h (ranging between 1 and 6 h), with the volume of distribution and protein binding potential being similar between rats and humans (Caccia *et al.*, 1990). Furthermore, the mean whole brain concentrations of the parent compound (fluoxetine) and its metabolite (norfluoxetine), after a single 10 mg/kg oral dose at 3 h, were 2.4 ± 0.5 and 2.5 ± 0.5 nmol/g, with no preference for concentrating in the different brain regions. After 30 h, these levels decreased to 0.02 ± 0.01 and 1.1 ± 0.5 nmol/g, whilst the norfluoxetine/fluoxetine ratio increased from 1.0 to 54 (Caccia *et al.*, 1990). Although not quantified here, available data (Berle *et al.*, 2004; Heikkinen *et al.*, 2003; Kim *et al.*, 2006; Oberlander *et al.*, 2005; Taddio *et al.*, 1996; Weissman *et al.*, 2004) suggests that fluoxetine is indeed expressed in the breast milk at a mean 3.96 ± 2.25[1] % of the maternal weight-adjusted dose. It would therefore follow that, because of the four-day wash-out period between the final dose administered to the postpartum dams (used for the current study), the dose to which the pups were exposed may have significantly decreased. Also, although rodents are generally weaned on PND21, it may be that some of them are already dependent on solid food (i.e., rat chow supplied) at this age, and therefore consuming less (if any) breast milk (and fluoxetine). Either way, this could explain why we were unable to detect fluoxetine in the juvenile brains. Follow-up studies should therefore measure fluoxetine concentrations immediately after the final maternal dose, to confirm our findings. The prolonged half-life of norfluoxetine most probably contributed to the detectable brain concentrations. And that norfluoxetine shares the serotonergic-enhancing potency of fluoxetine (Heikkinen *et al.*, 2003), could alter serotonin levels in the pre-pubertal brain.

In this regard, whole brain serotonin, its metabolite (5-hydroxyindoleacetic acid) and serotonin turnover of pre-pubertal male and female FSL rats, was unaffected by passively administered fluoxetine (Figure 4-1 and Table 4-2). Although unexpected, this is supported by the work of Epperson and colleagues (2003) who reported comparable baseline and post-exposure plasma serotonin levels in the babies of breastfeeding mothers treated with fluoxetine. More recently,

[1] *Mean ± standard deviation.*

de Andrade Silva and colleagues (2023), reported that 21-days of 10 mg/kg of sub-cutaneous fluoxetine did not induce any serotonin transporter or receptor expression differences in the hippocampus of juvenile Wistar rats. These, together with the current findings, support the results of Zaccarelli-Magalhães (2020), reporting no behavioural changes observed in Wistar offspring, exposed to escalating doses of passively administered fluoxetine.

As for the effect on redox state, we observed that passively administered fluoxetine further compromised whole antioxidant defences in male and female FSL pups, as indicated by decreased GSH (Table 4-3) and a GSH/GSSG ratio (Figure 4-2). It must however be noted here that these redox state differences are dependent on one data point, identified as a statistical outlier. However, because this specific sample had no obvious anatomical defect, nor was it identified as an outlier in the serotonergic analyses, it was included in the analysis. To promote transparency, even when excluded, a strong trend for this fluoxetine effect remains (Table 4-3), validating our findings and interpretation thereof. Regardless, our findings are similar to that of de Andrade Silva and colleagues (2023), who observed decreased hippocampal GSH/GSSG ratios, as well as decreased glutathione *S*-transferase (a family of enzymes, involved in reducing oxidative stress by conjugating GSH and forming non-toxic products, which has been shown to be reduced in depressed patients (Gawryluk *et al.*, 2011)). What is however interesting is that hippocampal malondialdehyde, superoxide dismutase and BDNF were unaffected, whereas the NAD/NADH[1] ratio was increased in these pups – altogether suggesting decreased oxidative stress damage, and improved mitochondrial function (de Andrade Silva *et al.*, 2023). These are interesting observations, as Dalmizrak and colleagues (2019) have argued that although fluoxetine is known to decrease glutathione reductase (the enzyme responsible for regulating glutathione levels), and consequently decrease antioxidant defences and increase oxidative stress, this effect could be beneficial in combating intracellular abnormalities, such as tumour cells. That no evidence of increased oxidative stress damage (i.e., unaltered malondialdehyde and BDNF levels) were observed in a similar investigation (de Andrade Silva *et al.*, 2023), could either be explained by compensatory mitochondrial mechanisms (i.e., increased NAD/NADH), and/or by the mitochondrial altering effects, induced by fluoxetine (Emmerzaal *et al.*, 2021). Either way, these observations point towards a more complicated redox state effect of passively administered fluoxetine that warrants further investigation. Moreover, whether these neurochemical effects would benefit or impair behaviour in these juvenile animals, remains unclear and must also be investigated in prospective studies. Finally, although passively administered fluoxetine appears to decrease

[1] *Nicotinamide adenine dinucleotide in its oxidized ($NAD^+$) and reduced (NADH) forms.*

the antioxidant defences, direct markers of oxidative stress damage, such as malondialdehyde or even 8-hydroxy-2'-deoxyguanosine, must be measured in prospective studies to conclude whether the reported neurochemical effects are indeed deleterious.

# CHAPTER 5: CONCLUSION, LIMITATIONS, AND FUTURE RESEARCH RECOMMENDATIONS

Based on the results and discussion of Chapter 4, this chapter addresses each of the research questions outlined in Chapter 1. These answers are then used to formulate a general conclusion and response to the overarching research question, posed in Section 1.3. Following this conclusion, the shortcomings and limitations of the current study are highlighted and used to guide further studies into this research topic by suggesting methodology to be investigated.

### Study question one

*Are there neurochemical differences in juvenile (PND21) FSL rats, compared to FRL controls?*

**Yes**. Although only serotonin and markers of redox state were measured, the current findings highlighted strain differences in terms of the latter. These findings suggest a compromised antioxidant defence system in the brain of pre-pubertal FSL rats, that may contribute to brain atrophy (Whitney *et al.*, 2023b) and the depressive-like phenotype reported by others. In terms of the current report, the null hypothesis (Section 1.5), can therefore, respectively be accepted (for serotonin) and rejected (for redox state).

### Study question two

*Can the concentration of passively administered fluoxetine to reach the juvenile brain be quantified? If indeed, what is this concentration?*

**Yes**. Although whole brain fluoxetine levels were below the limit of detection, we were able to successfully quantify norfluoxetine in the whole brains of pre-pubertal male and female FSL rats. Based on the current findings, passively administered fluoxetine resulted in an average norfluoxetine concentration of 41.28 ± 6.47 ng/g, which translates to 0.0014 ± 0.003 % of the mean daily fluoxetine dose administered to the lactating dams during the early postpartum period and following a four-day wash-out period.

### Study question three

*What are the effects of passively administered fluoxetine on serotonin levels and markers associated with mitochondrial function and oxidative stress?*

Based on the current findings, passively administered fluoxetine had no effect on whole brain serotonin levels, or the metabolism thereof. In contrast, passively administered fluoxetine

appears to further decrease antioxidant defences, compared to treatment naïve controls. As to whether this decrease is detrimental to the depressive-like phenotype of the juvenile FSL rat, remains unknown, and requires further investigation. Based on these findings (including those related to Study question 1), we can accept the null hypothesis that passively administered fluoxetine will not reverse the redox state deficit of pre-pubertal male and female FSL rats.

**Study question four**

*Does sex influence the outcomes of research questions one, two and three?*

**No.** There were no obvious or statistically significant sex differences in any of the parameter, measured in the current study. This could be explained by the fact that the pups were pre-pubertal when hormonal influences are non-significant. We can therefore accept the null hypothesis for this specific study question.

## 5.1 Conclusion

In this research work, we were able to quantify whole brain norfluoxetine concentrations of passively administrated fluoxetine and evaluate the serotonergic and redox state effect in the developing brain of a pre-pubertal rodent model of depression. Our findings confirm that passively administered fluoxetine does reach the infant brain in the form of norfluoxetine, which may manipulate processes of oxidative stress regulation. As to the nature of this manipulation, further studies are required to determine whether the observed decrease in antioxidant defences adversely influence juvenile behaviour. Taken together, further studies into the long-term bio-behavioural effects are needed to effectively inform breastfeeding mothers on the safety of antidepressant-use during the postpartum period.

## 5.2 Limitations and future recommendations

Several limitations were identified in the current study together with questions that should addressed in future studies. These are briefly described and elaborated on, below:

**Limitation 1**

**Including broader neurochemical profile analyses.** Because the current study only investigated the serotonergic and oxidative stress effects of passively administered fluoxetine, prospective studies should also include other markers that potentially could have been affected. To this end, brain-derived neurotrophic fact (BDNF), norepinephrine and other markers related to oxidative stress (i.e., malondialdehyde and/or 8-hydroxy-2'-deoxyguanosine) and

mitochondrial function (complex respiration and/or NAD/NADH[1]) would be valuable considerations. Although the serotonergic pathways mature earlier than the adrenergic ones, neurochemical imbalances caused by early-life insults could offset the developmental trajectory and function of the noradrenergic system, leading to bio-behavioural deficits. The effects of passively administered fluoxetine on the antioxidant defences also require further investigation, to determine whether the hypothesized mitochondrial compensatory mechanisms are indeed induced.

**Limitation 2**

**Including behavioural analyses.** Although not practical in the current study, prospective studies should investigate the behavioural effects of passively administered fluoxetine in the FSL rats, to be correlated with the mentioned neurochemical analyses. Potential behavioural analyses could include the forced swim test (behavioural despair), novel object recognition test (cognitive function), open field test (general locomotor activity and anxiety-like behaviour), sucrose preference test (anhedonia), and the novelty suppressed feeding test (anxiety and motivation) to better understand the impact of passively administered fluoxetine on offspring development.

**Limitation 3**

**Investigating the developmental stress-sensitivity of FSL rats exposed to passively administered fluoxetine.** Linking to the above-mentioned shortcoming of not being able to include behavioural analyses, future studies must also consider analysing the bio-behavioural profile of FSL rats, exposed to passively administered fluoxetine, at different developmental ages. Because children being exposed to passively administered fluoxetine are assumed to have a greater risk for developing depression (because of the genetic risk factor, and an assumed accurate maternal depression diagnosis), it would be valuable to determine whether these children may also be more sensitive to external stressors. To this end, follow-up studies could also include an external stressor, such as maternal or social isolation, to determine whether the passively exposed offspring, present with any bio-behavioural evidence of an altered stress-response and sensitivity.

[1] *Nicotinamide adenine dinucleotide in its oxidized ($NAD^+$) and reduced (NADH) forms.*

# ADDENDUM A: ETHICAL APPROVAL

Ethical approval was both granted (NWU) and waived (Wits) by the necessary Institutions – the certificates are presented below. For context, because the neurochemical analyses were performed at the North-West University, ethical approval had to be gained from the AnimCare-REC Committee, whilst ethical approval (or waiver) was also required from University of the Witwatersrand, to whom the degree belongs to. As alluded to in Chapter 1, ethical approval for the use of these samples is covered by application NWU-00434-21-A5.

## A1 Ethical approval by North-West University

Private Bag X1290, Potchefstroom
South Africa 2520

Tel: 086 016 9698
Web: http://www.nwu.ac.za/

**North-West University Animal Care, Health and Safety Research Ethics Committee (NWU-AnimCareREC)**

Tel: 018 299-1208
Email: Ethics-AnimCare@nwu.ac.za (for animal studies)

10 August 2023

### ETHICS APPROVAL LETTER OF STUDY

Based on approval by the North-West University Animal Care, Health and Safety Research Ethics Committee (NWU-AnimCareREC) on 10/08/2023, the NWU-AnimCareREC hereby approves your study as indicated below. This implies that the NWU-AnimCareREC grants its permission that, provided the general conditions specified below are met and pending any other authorisation that may be necessary, the study may be initiated, using the ethics number below.

**Study title: Determining brain concentrations of passively administered fluoxetine in Flinders sensitive line rat offspring and the neurochemical effects thereof**
**Principal Investigator/Study Supervisor/Researcher: Dr SF Steyn**
**Student: -**

**Ethics number**:

| N | W | U | - | 0 | 0 | 7 | 8 | 9 | - | 2 | 3 | - | A | 5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Institution | | | | Study Number | | | | | | Year | | | Status | |

Status: S = Submission; R = Re-Submission; P = Provisional Authorisation; A = Authorisation

**Application Type: Single study**
**Commencement date: 10/08/2023**
**Expiry date: 31/08/2024**
**Risk:** Category 0

**Approval of the study is provided for a year, after which continuation of the study is dependent on receipt and review of an annual monitoring report and the concomitant issuing of a letter of continuation. A monitoring report is required at the end of August annually until completion of the study.**

**General conditions:**

*While this ethics approval is subject to all declarations, undertakings and agreements incorporated and signed in the application form, the following general terms and conditions will apply:*

- *The principal investigator/study supervisor/researcher must report in the prescribed format to the NWU-AnimCareREC:*
  - *Annually on the monitoring of the study, whereby a letter of continuation will be provided annually, and upon completion of the study; and*
  - *without any delay in case of any adverse event or incident (or any matter that interrupts sound ethical principles) during the course of the study.*
- *The approval applies strictly to the proposal as stipulated in the application form. Should any amendments to the proposal be deemed necessary during the course of the study, the principal investigator/study supervisor/researcher must apply for approval of these amendments at the NWU-AnimCareREC, prior to implementation. Should there be any deviations from the study proposal without the necessary approval of such amendments, the ethics approval is immediately and automatically forfeited.*
- *Annually a number of studies may be randomly selected for active monitoring.*

9.1.5.4.2 Ethics Approval Letter of Study 1

- *The date of approval indicates the first date that the study may be started.*
- *In the interest of ethical responsibility, the NWU-AnimCareREC reserves the right to:*
  - *request access to any information or data at any time during the course or after completion of the study;*
  - *to ask further questions, seek additional information, require further modification or monitor the conduct of your research or the informed consent process;*
  - *withdraw or postpone approval if:*
    - *any unethical principles or practices of the study are revealed or suspected;*
    - *it becomes apparent that any relevant information was withheld from the NWU-AnimCareREC or that information has been false or misrepresented;*
    - *submission of the annual monitoring report, the required amendments, or reporting of adverse events or incidents was not done in a timely manner and accurately; and/or*
    - *new institutional rules, national legislation or international conventions deem it necessary.*
- *NWU-AnimCareREC can be contacted for further information via Ethics-AnimCare@nwu.ac.za or 018 299 1208*

NWU-AnimCareREC would like to remain at your service and wishes you well with your study. Please do not hesitate to contact the NWU-AnimCareREC for any further enquiries or requests for assistance.

Yours sincerely,



Digitally signed by
Christiaan B Brink
(Tiaan)
Date: 2023.08.11
14:25:56 +02'00'

Chairperson: NWU-AnimCareREC

Current details: (22654704) G:\One Drive\NWU-AnimCareREC\9.1.5.1_NWU-AnimCareREC Ethics\NWU-00789-23-A5 \9.1.5.1.1_FV\9.1.5.4_Approval

File Reference: 9.1.5.4

## A2 Ethical waiver by the University of the Witwatersrand




**ANIMAL RESEARCH ETHICS COMMITTEE**
Registration number: AREC-101210-002

Date:25/04/2023

**Certificate reference:** Waiver 25-04-2023-O
**Category:** O
**Applicant:** Stephan Steyn
**Department:** School of Pharmacy and Pharmacology (WITS)
**Tel:** 072 176 6624; **Email:** Stephan.steyn@nwu.ac.za

**Re: Waiver from the Animal Ethics Research Committee of the University of the Witwatersrand**

This letter is to confirm that Stephan Steyn, a MMed student at the School of Pharmacy and Pharmacology (#2632279) under the supervision of Prof Kondiah and Dr Padayachee (School of Pharmacy and Pharmacology, WITS), does not require full Animal Ethics Research Committee clearance to undertake the work titled **'Determining brain concentrations of passively administered fluoxetine in Flinders sensitive line (FSL) rat offspring and hte neurochemical effects thereof'**.

**Reason for waiver**
The project is using samples (brain) already collected at North West University (AnimCare approval number: NWU-00434-21-A5).

**Details of the study**
The current study aims to measure fluoxetine (and norfluoxetine) concentrations in the whole brains of 21-day old male and female FSL pups, born to dams treated with 10 mg/kg fluoxetine during the postpartum period. The researchers further aim to measure serotonin levels, and markers relating to mitochondrial function. Whole brain fluoxetine and norfluoxetine levels will be measured as recently described by Oosthuizen (2022). Secondly, quantification of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), GSH (glutathione) and GSSG (glutathione disulfide) will be determined using liquid chromatography/mass spectrometry (LC-MS), as described by Whitney (2022). Finally, 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels will be measured via an adapted LC-MS method, described by Wang and colleagues (2016). These markers will all be LC-MS analysed in our own laboratory (Centre of Excellence for Pharmaceutical Sciences, Department of Pharmacology, Faculty of Health Sciences, NWU).

The individuals covered by the waiver are Stephan Steyn, Prof Kondiah and Dr Padayachee (School of Pharmacy and Pharmacology, WITS).

Please contact me should you require further information.

Yours sincerely



A/Prof Frederic Michel
Chair: Animal Research Ethics Committee
University of the Witwatersrand

*References:*
*Oosthuisen, H. The effects of post-partum fluoxetine and low intensity exercise on the depressive-like behaviour of FSL and FRL rats, Pharmacology, North-West University, RSA, 2022, p. 180 (MSc dissertation).*
*Wang et al. 2016. Environ Sci Pollut Res Int. 23(17):17496-502.*
*Whitney, A. An investigation into the effects of perinatal and pre-pubertal low intensity exercise in the FSL rat exposed to early-life adversity, Pharmacology, North-West University, RSA, 2022, p. 155 (MSc dissertation).*

## A3 Research proposal approval certificate

UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

Private Bag 3 Wits, 2050
Fax: 027117172119
Tel: 02711 7172076

Reference: Mrs Sandra Benn
E-mail: sandra.benn@wits.ac.za

21 September 2023
Person No: 2632279
PAG

Dr SF Steyn
Njala street
Njala Park
Baillie Park
2531
South Africa

Dear Dr Stephanus Steyn


**Master of Science in Medicine: Approval of Title**

We have pleasure in advising that your proposal entitled *Brain concentrations and the neurochemical effects of passively administered fluoxetine in Flinders sensitive line rat offspring* has been approved. Please note that any amendments to this title have to be endorsed by the Faculty's higher degrees committee and formally approved.

Yours sincerely

Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences

## ADDENDUM B: TURNITIN SUMMARY REPORT



20267398:SF_Steyn_2632279_MMed_dissertation_-_Chapters_2-5_Turnitin.docx

ORIGINALITY REPORT

| 13% | 13% | 0% | 0% |
|---|---|---|---|
| SIMILARITY INDEX | INTERNET SOURCES | PUBLICATIONS | STUDENT PAPERS |

PRIMARY SOURCES

| | | |
|---|---|---|
| 1 | v-des-dev-lnx1.nwu.ac.za<br>Internet Source | 7% |
| 2 | repository.nwu.ac.za<br>Internet Source | 6% |

| | | | |
|---|---|---|---|
| Exclude quotes | On | Exclude matches | < 5% |
| Exclude bibliography | On | | |

# REFERENCES

Abildgaard, A., Elfving, B., Hokland, M., Lund, S. & Wegener, G. 2017. Probiotic treatment protects against the pro-depressant-like effect of high-fat diet in Flinders sensitive line rats. *Brain, behavior, and immunity*, 65:33-42. https://doi.org/10.1016/j.bbi.2017.04.017

Abildgaard, A., Solskov, L., Volke, V., Harvey, B.H., Lund, S. & Wegener, G. 2011. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. *Psychoneuroendocrinology*, 36(5):623-633. https://doi.org/10.1016/j.psyneuen.2010.09.004

Adam-Vizi, V. 2005. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non–electron transport chain sources. *Antioxidants & redox signaling*, 7(9-10):1140-1149. https://doi.org/10.1089/ars.2005.7.1140

Adibi, A., Golitaleb, M., Farrahi-Ashtiani, I., Pirani, D., Yousefi, K., Jamshidbeigi, Y. & Sahebi, A. 2021. The prevalence of generalized anxiety disorder among health care workers during the COVID-19 pandemic: a systematic review and meta-analysis. *Frontiers in psychiatry*, 12:658846. https://doi.org/10.3389/fpsyt.2021.658846

Aitken, A.R. & Törk, I. 1988. Early development of serotonin-containing neurons and pathways as seen in wholemount preparations of the fetal rat brain. *Journal of comparative neurology*, 274(1):32-47. https://doi.org/10.1002/cne.902740105

Allen, J., Romay-Tallon, R., Brymer, K.J., Caruncho, H.J. & Kalynchuk, L.E. 2018. Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. *Frontiers in neuroscience*, 12:386. https://doi.org/10.3389/fnins.2018.00386

American Psychiatric Association. 2013a. Specifiers of depressive disorders. In. *Diagnostic and statistical manual of mental disorders*. 5th. Arlington: American Psychiatric Publishing. pp. 184-188.

American Psychiatric Association. 2013b. Major depressive disorder. In. *Diagnostic and statistical manual of mental disorders*. 5th. Arlington: American Psychiatric Publishing. pp. 155-168.

American Psychological Association. 2009. *Publication Manual of the American Psychological Association*. 6th. Washington, USA: American Psychological Association.

American Psychological Association. 2019. *APA clinical practice guideline for the treatment of depression across three age cohorts*. https://www.apa.org/depression-guideline/guideline.pdf Date of access: 17 Sep 2023.

Andersen, S.L. 2003. Trajectories of brain development: point of vulnerability or window of opportunity? *Neuroscience & biobehavioral reviews*, 27(1):3-18. https://doi.org/10.1016/s0149-7634(03)00005-8

Andersen, S.L. & Navalta, C.P. 2011. Annual research review: new frontiers in developmental neuropharmacology: can long-term therapeutic effects of drugs be optimized through carefully timed early intervention? *Journal of child psychology and psychiatry*, 52(4):476-503. https://doi.org/10.1111/j.1469-7610.2011.02376.x

Anderson, G. & Maes, M. 2013. Postpartum depression: psychoneuroimmunological underpinnings and treatment. *Neuropsychiatric disease and treatment*, 9:277-287. https://doi.org/10.2147/NDT.S25320

Andrews, P.W., Bharwani, A., Lee, K.R., Fox, M. & Thomson, J.A. 2015. Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. *Neuroscience & biobehavioral reviews*, 51:164-188. https://doi.org/10.1016/j.neubiorev.2015.01.018

Appleby, L., Warner, R., Whitton, A. & Faragher, B. 1997. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. *BMJ*, 314(7085):932. https://doi.org/10.1136/bmj.314.7085.932

Barbosa, M.A., Veríssimo, L.F., Gerardin, D.C., Pelosi, G.G., Ceravolo, G.S. & Moreira, E.G. 2019. Maternal exposure to fluoxetine during gestation and lactation does not alter plasma concentrations of testosterone, oestrogen or corticosterone in peripubertal offspring. *Reproduction, fertility and development*, 31(5):1002-1008. https://doi.org/10.1071/RD18279

Barhafumwa, B., Dietrich, J., Closson, K., Samji, H., Cescon, A., Nkala, B., ... Gray, G. 2016. High prevalence of depression symptomology among adolescents in Soweto, South Africa associated with being female and cofactors relating to HIV transmission. *Vulnerable children and youth studies*, 11(3):263-273. https://doi.org/10.1080/17450128.2016.1198854

Battle, C.L., Salisbury, A.L., Schofield, C.A. & Ortiz-Hernandez, S. 2013. Perinatal antidepressant use: understanding women's preferences and concerns. *Journal of psychiatric practice*, 19(6):443-453. https://doi.org/10.1097/01.pra.0000438183.74359.46

Beckley, E.H. & Finn, D.A. 2007. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. *Pharmacology biochemistry and behavior*, 87(4):412-419. https://doi.org/10.1016/j.pbb.2007.05.017

Beinschroth, K.M. 2020. *The relationship between maternal postpartum depression/postpartum anxiety and duration of breastfeeding.* California Baptist University. (Masters dissertation). https://www.proquest.com/docview/2449965670?pq-origsite=gscholar&fromopenview=true

Bekku, N. & Yoshimura, H. 2005. Animal model of menopausal depressive-like state in female mice: prolongation of immobility time in the forced swimming test following ovariectomy. *Psychopharmacology*, 183:300-307. https://doi.org/10.1007/s00213-005-0179-0

Berle, J.O., Steen, V.M., Aamo, T.O., Breilid, H., Zahlsen, K. & Spigset, O. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. *Journal of clinical psychiatry*, 65(9):1228-1234. https://doi.org/10.4088/jcp.v65n0911

Bloch, M., Daly, R.C. & Rubinow, D.R. 2003. Endocrine factors in the etiology of postpartum depression. *Comprehensive psychiatry*, 44(3):234-246. https://doi.org/10.1016/S0010-440X(03)00034-8

Boulle, F., Pawluski, J.L., Homberg, J.R., Machiels, B., Kroeze, Y., Kumar, N., ... Van den Hove, D.L. 2016. Prenatal stress and early-life exposure to fluoxetine have enduring effects on anxiety and hippocampal BDNF gene expression in adult male offspring. *Developmental psychobiology*, 58(4):427-438. https://doi.org/10.1002/dev.21385

Braw, Y., Malkesman, O., Merlender, A., Bercovich, A., Dagan, M., Maayan, R., ... Weller, A. 2006. Stress hormones and emotion-regulation in two genetic animal models of depression. *Psychoneuroendocrinology*, 31(9):1105-1116. https://doi.org/10.1016/j.psyneuen.2006.07.003

Brown, J.V.E., Wilson, C.A., Ayre, K., Robertson, L., South, E., Molyneaux, E., ... Khalifeh, H. 2021. Antidepressant treatment for postnatal depression. *Cochrane database of systematic reviews*, (2):CD013560. https://doi.org/10.1002/14651858.CD013560.pub2

Brummelte, S. & Galea, L.A. 2010. Chronic corticosterone during pregnancy and postpartum affects maternal care, cell proliferation and depressive-like behavior in the dam. *Hormones and behavior*, 58(5):769-779. https://doi.org/10.1016/j.yhbeh.2010.07.012

Buelt, A. & McQuaid, J.R. 2023. Comparing clinical guidelines for the management of major depressive disorder. *American family physician*, 107(2):123-124.

Caccia, S., Cappi, M., Fracasso, C. & Garattini, S. 1990. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. *Psychopharmacology*, 100:509-514. https://doi.org/10.1007/BF02244004

Cameron, E.E., Joyce, K.M., Delaquis, C.P., Reynolds, K., Protudjer, J.L. & Roos, L.E. 2020. Maternal psychological distress & mental health service use during the COVID-19 pandemic. *Journal of affective disorders*, 276:765-774. https://doi.org/10.1016/j.jad.2020.07.081

Çankaya, S. 2020. The effect of psychosocial risk factors on postpartum depression in antenatal period: a prospective study. *Archives of psychiatric nursing*, 34(3):176-183. https://doi.org/10.1016/j.apnu.2020.04.007

Caropreso, L., de Azevedo Cardoso, T., Eltayebani, M. & Frey, B.N. 2020. Preeclampsia as a risk factor for postpartum depression and psychosis: a systematic review and meta-analysis. *Archives of women's mental health*, 23:493-505. https://doi.org/10.1007/s00737-019-01010-1

Centers for disease control and prevention. 2020. *Children's mental health*. https://www.cdc.gov/childrensmentalhealth/data.html#ref Date of access: 27 Jun 2023.

Centers for disease control and prevention. 2023. *Depression during and after pregnancy*. https://www.cdc.gov/reproductivehealth/features/maternal-depression/index.html Date of access: 01 Sep 2023.

Chen, F., Wegener, G., Madsen, T.M. & Nyengaard, J.R. 2013. Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment. *Synapse*, 67(3):127-134. https://doi.org/10.1002/syn.21622

Chen, F., Ardalan, M., Elfving, B., Wegener, G., Madsen, T.M. & Nyengaard, J.R. 2018. Mitochondria are critical for BDNF-mediated synaptic and vascular plasticity of hippocampus following repeated electroconvulsive seizures. *International journal of neuropsychopharmacology*, 21(3):291-304. https://doi.org/10.1093/ijnp/pyx115

Chen, Q., Li, W., Xiong, J. & Zheng, X. 2022. Prevalence and risk factors associated with postpartum depression during the COVID-19 pandemic: a literature review and meta-analysis. *International journal of environmental research and public health*, 19(4):2219. https://doi.org/10.3390/ijerph19042219

Chugani, D.C., Muzik, O., Behen, M., Rothermel, R., Janisse, J.J., Lee, J. & Chugani, H.T. 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. *Annals of neurology*, 45(3):287-295. https://doi.org/10.1002/1531-8249(199903)45:3

Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S.E., Qin, B., Whittington, C., ... Leucht, S. 2016. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *The Lancet*, 388(10047):881-890. https://doi.org/10.1016/S0140-6736(16)30385-3

Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., ... Geddes, J.R. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*, 74:311-312. https://doi.org/10.1016/S0140-6736(17)32802-7

Clark, C.E., Rasgon, N.L., Reed, D.E. & Robakis, T.K. 2019. Depression precedes, but does not follow, gestational diabetes. *Acta Psychiatrica Scandinavica*, 139(4):311-321. https://doi.org/10.1111/acps.12998

Cooper, M.C., Kilvert, H.S., Hodgkins, P., Roskell, N.S. & Eldar-Lissai, A. 2019. Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression. *CNS drugs*, 33:1039-1052. https://doi.org/10.1007/s40263-019-00672-w

Cotman, C.W. & Berchtold, N.C. 2002. Exercise: A behavioral intervention to enhance brain health and plasticity. *Trends in neurosciences*, 25(6):295-301. https://10.1016/s0166-2236(02)02143-4

Cree, R.A., Bitsko, R.H., Robinson, L.R., Holbrook, J.R., Danielson, M.L., Smith, C., ... Peacock, G. 2018. Health care, family, and community factors associated with mental, behavioral, and developmental disorders and poverty among children aged 2-8 years - United States, 2016. *Morbidity and mortality weekly report*, 67(50):1377-1383. https://doi.org/10.15585/mmwr.mm6750a1

Cumming, G. 2013. The new statistics: why and how. *Psychological science*, 25(1):7-29. https://doi.org/10.1177/0956797613504966

Cumming, G., Fidler, F., Leonard, M., Kalinowski, P., Christiansen, A., Kleinig, A., ... Wilson, S. 2007. Statistical reform in psychology is anything changing? *Psychological science*, 18(3):230-232. https://doi.org/10.1111/j.1467-9280.2007.01881.x

Dadi, A.F., Miller, E.R. & Mwanri, L. 2020. Postnatal depression and its association with adverse infant health outcomes in low-and middle-income countries: a systematic review and meta-analysis. *BMC pregnancy and childbirth*, 20(1):1-15. https://doi.org/10.1186/s12884-020-03092-7

Dalmizrak, O., Teralı, K., Asuquo, E.B., Ogus, I.H. & Ozer, N. 2019. The relevance of glutathione reductase inhibition by fluoxetine to human health and disease: insights derived from a combined kinetic and docking study. *The Protein journal*, 38(5):515-524. https://doi.org/10.1007/s10930-019-09834-7

Darmani, N.A. & Ahmad, B. 1999. Long-term sequential determination of behavioral ontogeny of 5-$HT_{1A}$ and 5-$HT_2$ receptor functions in the rat. *Journal of pharmacology and experimental therapeutics*, 288(1):247-253.

Daval, G., Verge, D., Becerril, A., Gozlan, H., Spampinato, U. & Hamon, M. 1987. Transient expression of 5-$HT_{1A}$ receptor binding sites in some areas of the rat CNS during postnatal development. *International journal of developmental neuroscience*, 5(3):171-180. https://doi.org/10.1016/0736-5748(87)90027-x

Davis, R. 2023. SA 'Killer Mum' Lauren Dickason's New Zealand murder trial is a chillingly strange, sad and complex affair. *Daily Maverick*, 16 Aug 2023. https://www.dailymaverick.co.za/article/2023-08-05-south-africa-killer-mum-lauren-dickason-new-zealand-murder-trial/.

de Andrade Silva, S.C., de Lemos, M.D.T., Santos-Junior, O.H., de Oliveira Rodrigues, T., Silva, T.L., Tavares, G.A., ... Lagranha, C.J. 2023. The immediate effect of overnutrition and fluoxetine treatment during the critical period of development on the hippocampus. *Neurochemistry international*, 162:105454. https://doi.org/10.1016/j.neuint.2022.105454

De Crescenzo, F., Perelli, F., Armando, M. & Vicari, S. 2014. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. *Journal of affective disorders*, 152:39-44. https://doi.org/10.1016/j.jad.2013.09.019

DeBattista, C. 2021. Antidepressant agents. In: Katzung, B.G. & Trevor, A.J., eds. *Basic & clinical pharmacology*. 15th. USA: McGraw-Hill Education. Chapter 30. p *ebook*. https://accesspharmacy-mhmedical-com.nwulib.idm.oclc.org/book.aspx?bookid=2988 Date of access: 20 Sep 2023.

Deligiannidis, K.M., Kroll-Desrosiers, A.R., Mo, S., Nguyen, H.P., Svenson, A., Jaitly, N., ... Shaffer, S.A. 2016. Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression. *Psychoneuroendocrinology*, 70:98-107. https://doi.org/10.1016/j.psyneuen.2016.05.010

Dennis, C.-L.E. & Stewart, D.E. 2004. Treatment of postpartum depression, part 1: a critical review of biological interventions. *Journal of clinical psychiatry*, 65(9):1242-1251. https://doi.org/10.4088/jcp.v65n0914

Desimoni, E. & Brunetti, B. 2015. About estimating the limit of detection by the signal to noise approach. *Pharmaceutica Analytica Acta*, 6(3):1-4. https://doi.org/10.4172/2153-2435.1000355

Dias, C.C. & Figueiredo, B. 2015. Breastfeeding and depression: a systematic review of the literature. *Journal of affective disorders*, 171:142-154. https://doi.org/10.1016/j.jad.2014.09.022

Dietz, L.J., Birmaher, B., Williamson, D.E., Silk, J.S., Dahl, R.E., Axelson, D.A., ... Ryan, N.D. 2008. Mother-child interactions in depressed children and children at high risk and low risk for future depression. *Journal of the American Academy of child & adolescent psychiatry*, 47(5):574-582. https://doi.org/10.1097/CHI.0b013e3181676595

Dobbing, J. & Sands, J. 1979. Comparative aspects of the brain growth spurt. *Early human development*, 3(1):79-83. https://doi.org/10.1016/0378-3782(79)90022-7

Dominiak, M., Antosik-Wojcinska, A.Z., Baron, M., Mierzejewski, P. & Swiecicki, L. 2021. Recommendations for the prevention and treatment of postpartum depression. *Ginekologia Polska*, 92(2):153-164. https://doi.org/10.5603/GP.a2020.0141

Dori, I., Dinopoulos, A., Blue, M.E. & Parnavelas, J.G. 1996. Regional differences in the ontogeny of the serotonergic projection to the cerebral cortex. *Experimental neurology*, 138(1):1-14. https://doi.org/10.1006/exnr.1996.0041

Doyle, F.L. & Klein, L. 2020. Postnatal depression risk factors: an overview of reviews to inform COVID-19 research, clinical, and policy priorities. *Frontiers in global women's health*, 1:577273. https://doi.org/10.3389/fgwh.2020.577273

Drzewiecki, C.M., Willing, J. & Juraska, J.M. 2020. Influences of age and pubertal status on number and intensity of perineuronal nets in the rat medial prefrontal cortex. *Brain structure and function*, 225(8):2495-2507. https://doi.org/10.1007/s00429-020-02137-z

du Jardin, K.G., Liebenberg, N., Müller, H.K., Elfving, B., Sanchez, C. & Wegener, G. 2016. Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. *Psychopharmacology (Berl)*, 233(14):2813-2825. https://doi.org/10.1007/s00213-016-4327-5

du Sert, N.P., Hurst, V., Ahluwalia, A., Alam, S., Avey, M., Baker, M., ... Wurbel, H. 2020. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *PLoS Biology*, 16(1):242. https://doi.org/10.1371/journal.pbio.3000410

Ducottet, C., Griebel, G. & Belzung, C. 2003. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. *Progress in neuro-psychopharmacology and biological psychiatry*, 27(4):625-631. https://doi.org/10.1016/S0278-5846(03)00051-4

Eldar-Lissai, A., Cohen, J.T., Meltzer-Brody, S., Gerbasi, M.E., Chertavian, E., Hodgkins, P., ... Johnson, S.J. 2020. Cost-effectiveness of brexanolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. *Journal of managed care & specialty pharmacy*, 26(5):627-638. https://doi.org/10.18553/jmcp.2020.19306

Ellis, P.D. 2010. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. In. 1st. Cambridge (UK): Cambridge University Press. Chapter 41. p 173.

Emmerzaal, T.L., Nijkamp, G., Veldic, M., Rahman, S., Andreazza, A.C., Morava, E., ... Kozicz, T. 2021. Effect of neuropsychiatric medications on mitochondrial function: for better or for worse. *Neuroscience & biobehavioral reviews*, 127:555-571. https://doi.org/10.1016/j.neubiorev.2021.05.001

Enjalbert, A., Bourgoin, S., Hamon, M., Adrien, J. & Bockaert, J. 1978. Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system I. Development and distribution of serotonin and dopamine-sensitive adenylate cyclases in rat and guinea pig brain. *Molecular pharmacology*, 14(1):2-10.

Epperson, C.N., Jatlow, P.I., Czarkowski, K. & Anderson, G.M. 2003. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. *Pediatrics*, 112(5):e425. https://doi.org/10.1542/peds.112.5.e425

Fakhoury, M. 2016. Revisiting the serotonin hypothesis: implications for major depressive disorders. *Molecular neurobiology*, 53:2778-2786. https://doi.org/10.1007/s12035-015-9152-z

Federico, A., Cardaioli, E., Da Pozzo, P., Formichi, P., Gallus, G.N. & Radi, E. 2012. Mitochondria, oxidative stress and neurodegeneration. *Journal of the neurological sciences*, 322(1-2):254-262. https://doi.org/10.1016/j.jns.2012.05.030

Figueiredo, B., Canário, C. & Field, T. 2014. Breastfeeding is negatively affected by prenatal depression and reduces postpartum depression. *Psychological medicine*, 44(5):927-936. https://doi.org/10.1017/S0033291713001530

Frieder, A., Fersh, M., Hainline, R. & Deligiannidis, K.M. 2019. Pharmacotherapy of postpartum depression: Current approaches and novel drug development. *Central nervous system drugs*, 33(3):265-282. https://doi.org/10.1007/s40263-019-00605-7

Galea, L.A., Wide, J.K. & Barr, A.M. 2001. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. *Behavioural brain research*, 122(1):1-9. https://doi.org/10.1016/S0166-4328(01)00170-X

Gao, S.-Y., Wu, Q.-J., Sun, C., Zhang, T.-N., Shen, Z.-Q., Liu, C.-X., ... Huang, D.-H. 2018. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. *BMC medicine*, 16(1):1-14. https://doi.org/10.1186/s12916-018-1193-5

Gavin, N.I., Gaynes, B.N., Lohr, K.N., Meltzer-Brody, S., Gartlehner, G. & Swinson, T. 2005. Perinatal depression: a systematic review of prevalence and incidence. *Obstetrics & gynecology*, 106(5):1071-1083. https://doi.org/10.1097/01.AOG.0000183597.31630.db

Gawryluk, J.W., Wang, J.-F., Andreazza, A.C., Shao, L., Yatham, L.N. & Young, L.T. 2011. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. *International journal of neuropsychopharmacology*, 14(8):1069-1074. https://doi.org/10.1017/S1461145711000617

Gelaye, B., Rondon, M.B., Araya, R. & Williams, M.A. 2016. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. *The Lancet Psychiatry*, 3(10):973-982. https://doi.org/10.1016/S2215-0366(16)30284-X

Ghandour, R.M., Sherman, L.J., Vladutiu, C.J., Ali, M.M., Lynch, S.E., Bitsko, R.H. & Blumberg, S.J. 2019. Prevalence and treatment of depression, anxiety, and conduct problems in US children. *The journal of pediatrics*, 206:256-267.e253. https://doi.org/10.1016/j.jpeds.2018.09.021

Gobinath, A.R., Workman, J.L., Chow, C., Lieblich, S.E. & Galea, L.A. 2016. Maternal postpartum corticosterone and fluoxetine differentially affect adult male and female offspring on anxiety-like behavior, stress reactivity, and hippocampal neurogenesis. *Neuropharmacology*, 101:165-178. https://doi.org/10.1016/j.neuropharm.2015.09.001

Gobinath, A.R., Wong, S., Chow, C., Lieblich, S.E., Barr, A.M. & Galea, L.A. 2018. Maternal exercise increases but concurrent maternal fluoxetine prevents the increase in hippocampal neurogenesis of adult offspring. *Psychoneuroendocrinology*, 91:186-197. https://doi.org/10.1016/j.psyneuen.2018.02.027

Golden, G.S. 1982. A review of the neuroembryology of monoamine systems. *Brain research bulletin*, 9(1):553-558. https://doi.org/10.1016/0361-9230(82)90163-0

Green, P., Glozman, S., Kamensky, B. & Yavin, E. 1999. Developmental changes in rat brain membrane lipids and fatty acids: the preferential prenatal accumulation of docosahexaenoic acid. *Journal of lipid research*, 40(5):960-966. https://doi.org/10.1385/JMN:16:2-3:229

Grekin, R. & O'Hara, M.W. 2014. Prevalence and risk factors of postpartum posttraumatic stress disorder: a meta-analysis. *Clinical psychology review*, 34(5):389-401. https://doi.org/10.1016/j.cpr.2014.05.003

Guintivano, J., Byrne, E.M., Kiewa, J., Yao, S., Bauer, A.E., Aberg, K.A., ... Choi, K.W. 2023. Meta-Analyses of Genome-Wide Association Studies for postpartum depression. *American journal of psychiatry*:*Online | ahead of print*. https://doi.org/10.1176/appi.ajp.20230053

Hahn-Holbrook, J., Cornwell-Hinrichs, T. & Anaya, I. 2018. Economic and health predictors of national postpartum depression prevalence: a systematic review, meta-analysis, and meta-regression of 291 studies from 56 countries. *Frontiers in psychiatry*, 8:248.

Hall, P.L. & Papageorgiou, C. 2005. Negative thoughts after childbirth: development and preliminary validation of a self-report scale. *Depression and anxiety*, 22(3):121-129. https://doi.org/10.1002/da.20119

Hall, P.L. & Holden, S. 2008. Association of psychosocial and demographic factors with postpartum negative thoughts and appraisals. *The Journal of perinatal & neonatal nursing*, 22(4):275-281. https://doi.org/10.1097/01.JPN.0000341357.53069.ae

Hansson, S.R., Mezey, E. & Hoffman, B.J. 1998. Serotonin transporter messenger RNA in the developing rat brain: Early expression in serotonergic neurons and transient expression in non-serotonergic neurons. *Neuroscience*, 83(4):1185-1201. https://doi.org/10.1016/s0306-4522(97)00444-2

Happe, H.K., Bylund, D.B. & Murrin, L.C. 1999. Alpha-2 adrenergic receptor functional coupling to G proteins in rat brain during postnatal development. *Journal of pharmacology and experimental therapeutics*, 288(3):1134-1142.

Happe, H.K., Coulter, C.L., Gerety, M.E., Sanders, J.D., O'Rourke, M., Bylund, D.B. & Murrin, L.C. 2004. Alpha-2 adrenergic receptor development in rat CNS: an autoradiographic study. *Neuroscience*, 123(1):167-178. https://doi.org/10.1016/j.neuroscience.2003.09.004

Harden, T.K., Wolfe, B.B., Sporn, J.R., Perkins, J.P. & Molinoff, P.B. 1977. Ontogeny of β-adrenergic receptors in rat cerebral cortex. *Brain research*, 125(1):99-108. https://doi.org/10.1016/0006-8993(77)90362-6

Heikkinen, T., Ekblad, U., Palo, P. & Laine, K. 2003. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. *Clinical pharmacology & therapeutics*, 73(4):330-337. https://doi.org/10.1016/S0009-9236(02)17634-X

Hellgren, C., Åkerud, H., Skalkidou, A., Bäckström, T. & Sundström-Poromaa, I. 2014. Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. *Neuropsychobiology*, 69(3):147-153. https://doi.org/10.1159/000358838

Hendrick, V., Stowe, Z.N., Altshuler, L.L., Mintz, J., Hwang, S., Hostetter, A., ... Fukuchi, A. 2001. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. *Biological psychiatry*, 50(10):775-782. https://doi.org/10.1016/S0006-3223(01)01197-0

Herman, J.P., Mueller, N.K. & Figueiredo, H. 2004. Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration. *Annals of the New York Academy of Sciences*, 1018(1):35-45. https://doi.org/10.1196/annals.1296.004

Hesselberg, M.L., Wegener, G. & Buchholtz, P.E. 2016. Antidepressant efficacy of high and low frequency transcranial magnetic stimulation in the FSL/FRL genetic rat model of depression. *Behavioural brain research*, 314:45-51. https://doi.org/10.1016/j.bbr.2016.07.037

Hieronymus, F., Lisinski, A., Nilsson, S. & Eriksson, E. 2018. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. *Molecular psychiatry*, 23(8):1731-1736. https://doi.org/10.1038/mp.2017.147

Houwing, D.J., Staal, L., Swart, J.M., Ramsteijn, A.S., Wöhr, M., De Boer, S.F. & Olivier, J.D. 2019. Subjecting dams to early life stress and perinatal fluoxetine treatment differentially alters social behavior in young and adult rat offspring. *Frontiers in neuroscience*, 13:229. https://doi.org/10.3389/fnins.2019.00229

Hvilsom, A.S.T., Lillethorup, T.P., Iversen, P., Doudet, D.J., Wegener, G. & Landau, A.M. 2019. Cortical and striatal serotonin transporter binding in a genetic rat model of depression and in response to electroconvulsive stimuli. *European neuropsychopharmacology*, 29(4):493-500. https://doi.org/10.1016/j.euroneuro.2019.02.009

Jauhar, S., Arnone, D., Baldwin, D.S., Bloomfield, M., Browning, M., Cleare, A.J., ... Fu, C. 2023. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. *Molecular psychiatry*:1-4. https://doi.org/10.1038/s41380-023-02095-y

Jones, D., Letourneau, N. & Leger, L.D. 2019. Predictors of infant care competence among mothers with postpartum depression. *Clinical medicine insights: reproductive health*, 13:1179558119834910. https://doi.org/10.1177/1179558119834910

Kambeitz, J.P. & Howes, O.D. 2015. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. *Journal of affective disorders*, 186:358-366. https://doi.org/10.1016/j.jad.2015.07.034

Kanemaru, K., Hasegawa, S., Nishi, K. & Diksic, M. 2008. Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation. *Brain research bulletin*, 77(4):214-220.

Kato, T., Yamaguchi, T., Togari, A., Nagatsu, T., Yajima, T., Maeda, N. & Kumegawa, M. 1982. Ontogenesis of monoamine-synthesizing enzyme activities and biopterin levels in rat brain or salivary glands, and the effect of thyroxine administration. *Journal of neurochemistry*, 38(4):896-901. https://doi.org/10.1111/j.1471-4159.1982.tb05327.x

Kelsey, J.J. & Ward, K.E. 2020. Pregnancy and lactation: therapeutic considerations. In: Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D. & Ellingrod, V.L., eds. *Pharmacotherapy: a pathophysiologic approach*. 11th. USA: McGraw-Hill. Chapter 95. p *ebook*. https://accesspharmacy-mhmedical-com.nwulib.idm.oclc.org/book.aspx?bookid=2577 Date of access: 20 Sep 2023.

Kepser, L.-J. & Homberg, J.R. 2015. The neurodevelopmental effects of serotonin: a behavioural perspective. *Behavioural brain research*, 277:3-13. https://doi.org/10.1016/j.bbr.2014.05.022

Kim, J., Riggs, K.W., Misri, S., Kent, N., Oberlander, T.F., Grunau, R.E., ... Rurak, D.W. 2006. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. *British journal of clinical pharmacology*, 61(2):155-163. https://doi.org/10.1111/j.1365-2125.2005.02538.x

Kliewer, S.A., Goodwin, B. & Willson, T.M. 2002. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. *Endocrine reviews*, 23(5):687-702. https://doi.org/10.1210/er.2001-0038

Klinedinst, N.J. & Regenold, W.T. 2015. A mitochondrial bioenergetic basis of depression. *Journal of bioenergetics and biomembranes*, 47:155-171. https://doi.org/10.1007/s10863-014-9584-6

Konkol, R.J., Bendeich, E.G. & Breese, G.R. 1978. A biochemical and morphological study of the altered growth pattern of central catecholamine neurons following 6-hydroxydopamine. *Brain research*, 140(1):125-135. https://doi.org/10.1016/0006-8993(78)90242-1

LactMed®. 2023a. *Drugs and Lactation Database: Fluoxetine*. https://www.ncbi.nlm.nih.gov/books/NBK501186/ Date of access: 19 Sep 2023.

LactMed®. 2023b. *Drugs and Lactation Database: Brexanolone*. https://www.ncbi.nlm.nih.gov/books/NBK540687/ Date of access: 19 Sep 2023.

Lauder, J.M. & Bloom, F.E. 1974. Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. I. Cell differentiation. *Journal of comparative neurology*, 155(4):469-481. https://doi.org/10.1002/cne.901550407

Lauder, J.M. & Bloom, F.E. 1975. Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. II. Synaptogenesis. *Journal of comparative neurology*, 163(3):251-264. https://doi.org/10.1002/cne.901630302

Lee, G.C. & Burgees, D.S. 2020. Antimicrobial regimen selection. In: Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D. & Ellingrod, V.L., eds. *Pharmacotherapy: a pathophysiologic approach*. 11th. USA: McGraw-Hill. Chapter 123. p *ebook*. https://accesspharmacy-mhmedical-com.nwulib.idm.oclc.org/content.aspx?bookid=2577&sectionid=219315319 Date of access: 20 Sep 2023.

Lerch-Haner, J.K., Frierson, D., Crawford, L.K., Beck, S.G. & Deneris, E.S. 2008. Serotonergic transcriptional programming determines maternal behavior and offspring survival. *Nature neuroscience*, 11(9):1001-1003. https://doi.org/https://doi.org/10.1038/nn.2176

Levis, B., Negeri, Z., Sun, Y., Benedetti, A. & Thombs, B.D. 2020. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. *BMJ*, 371, https://doi.org/10.1136/bmj.m4022

Li, T. & Apte, U. 2015. Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. *Advances in pharmacology*, 74:263-302. https://doi.org/10.1016/bs.apha.2015.04.003

Lidov, H.G.W. & Molliver, M.E. 1982. Immunohistochemical study of the development of serotonergic neurons in the rat CNS. *Brain research bulletin*, 9(1):559-604. https://doi.org/10.1016/0361-9230(82)90164-2

Liu, X., Wang, S. & Wang, G. 2022. Prevalence and risk factors of postpartum depression in women: a systematic review and meta-analysis. *Journal of clinical nursing*, 31(19-20):2665-2677. https://doi.org/10.1111/jocn.16121

Locher, C., Koechlin, H., Zion, S.R., Werner, C., Pine, D.S., Kirsch, I., ... Kossowsky, J. 2017. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents a systematic review and meta-analysis. *JAMA psychiatry*, 74(10):1011-1020. https://doi.org/10.1001/jamapsychiatry.2017.2432

Loizou, L.A. 1972. The postnatal ontogeny of monoamine-containing neurones in the central nervous system of the albino rat. *Brain research*, 40(2):395-418. https://doi.org/10.1016/0006-8993(72)90142-4

Loizou, L.A. & Salt, P. 1970. Regional changes in monoamines of the rat brain during postnatal development. *Brain research*, 20(3):467-470. https://doi.org/10.1016/0006-8993(70)90177-0

Lopresti, A.L., Maker, G.L., Hood, S.D. & Drummond, P.D. 2014. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. *Progress in neuro-psychopharmacology and biological psychiatry*, 48:102-111. https://doi.org/10.1016/j.pnpbp.2013.09.017

Maguire, J., McCormack, C., Mitchell, A. & Monk, C. 2020. Neurobiology of meternal mental illness. *Handbook of clinical neurology*, 171:97-116. https://doi.org/10.1016/B978-0-444-64239-4.00005-9

Malkesman, O. & Weller, A. 2009. Two different putative genetic animal models of childhood depression - A review. *Progress in neurobiology*, 88(3):153-169. https://doi.org/10.1016/j.pneurobio.2009.03.003

Malkesman, O., Braw, Y., Ram, E., Maayan, R., Weizman, A., Kinor, N., ... Weller, A. 2008. Dehydroepiandrosterone and monoamines in the limbic system of a genetic animal model of childhood depression. *European neuropsychopharmacology*, 18(4):255-261. https://doi.org/10.1016/j.euroneuro.2007.06.007

Malkesman, O., Braw, Y., Zagoory-Sharon, O., Golan, O., Lavi-Avnon, Y., Schroeder, M., ... Weller, A. 2005. Reward and anxiety in genetic animal models of childhood depression. *Behavioural brain research*, 164(1):1-10.

Malkesman, O., Shayit, M., Genud, R., Zangen, A., Kinor, N., Maayan, R., ... Yadid, G. 2007. Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: A study in an animal model of childhood depression. *Neuroscience*, 149(3):573-581. https://doi.org/10.1016/j.neuroscience.2007.06.031

Malkesman, O., Braw, Y., Maayan, R., Weizman, A., Overstreet, D.H., Shabat-Simon, M., ... Weller, A. 2006. Two different putative genetic animal models of childhood depression. *Biological psychiatry*, 59(1):17-23. https://doi.org/10.1016/j.biopsych.2005.05.039

Manji, H., Kato, T., Di Prospero, N.A., Ness, S., Beal, M.F., Krams, M. & Chen, G. 2012. Impaired mitochondrial function in psychiatric disorders. *Nature reviews neuroscience*, 13(5):293-307. https://doi.org/10.1038/nrn3229

Markus, E.J. & Petit, T.L. 1987. Neocortical synaptogenesis, aging, and behavior: lifespan development in the motor-sensory system of the rat. *Experimental neurology*, 96(2):262-278. https://doi.org/10.1016/0014-4886(87)90045-8

Martinez-Torteya, C., Katsonga-Phiri, T., Rosenblum, K.L., Hamilton, L. & Muzik, M. 2018. Postpartum depression and resilience predict parenting sense of competence in women with childhood maltreatment history. *Archives of women's mental health*, 21:777-784. https://doi.org/10.1007/s00737-018-0865-7

Mattson, M.P., Gleichmann, M. & Cheng, A. 2008. Mitochondria in neuroplasticity and neurological disorders. *Neuron*, 60(5):748-766. https://doi.org/10.1016/j.neuron.2008.10.010

Melas, P., Lennartsson, A., Vakifahmetoglu-Norberg, H., Wei, Y., Åberg, E., Werme, M., ... Brene, S. 2013. Allele-specific programming of Npy and epigenetic effects of physical activity in a genetic model of depression. *Translational psychiatry*, 3(5):e255. https://doi.org/10.1038/tp.2013.31

Melón, L.C., Hooper, A., Yang, X., Moss, S.J. & Maguire, J. 2018. Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice. *Psychoneuroendocrinology*, 90:182-193. https://doi.org/10.1016/j.psyneuen.2017.12.003

Meltzer-Brody, S., Stuebe, A., Dole, N., Savitz, D., Rubinow, D. & Thorp, J. 2011. Elevated corticotropin releasing hormone (CRH) during pregnancy and risk of postpartum depression (PPD). *The Journal of clinical endocrinology & metabolism*, 96(1):E40-47. https://doi.org/10.1210/jc.2010-0978

Miller, A.H., Maletic, V. & Raison, C.L. 2009. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biological psychiatry*, 65(9):732-741. https://doi.org/10.1016/j.biopsych.2008.11.029

Miller, G.E., Chen, E. & Zhou, E.S. 2007. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. *Psychological bulletin*, 133(1):25. https://doi.org/10.1037/0033-2909.133.1.25

Ming, L. & Shinn-Yi, C. 2016. Modeling postpartum depression in rats: theoretic and methodological issues. *Zoological research*, 37(4):229. https://doi.org/10.13918/j.issn.2095-8137.2016.4.229

Mncube, K. & Harvey, B.H. 2022. Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment. *IBRO Neuroscience reports*, 13:284-298. https://doi.org/10.1016/j.ibneur.2022.08.009

Mohideen, K., Sudhakar, U., Balakrishnan, T., Almasri, M.A., Al-Ahmari, M.M., Al Dira, H.S., ... Khurshid, Z. 2021. Malondialdehyde, an oxidative stress marker in oral squamous cell carcinoma - A systematic review and meta-analysis. *Current Issues in molecular biology*, 43(2):1019-1035. https://doi.org/10.3390/cimb43020072

Mokwena, K.E. 2021. Neglecting maternal depression compromises child health and development outcomes, and violates children's rights in South Africa. *Children*, 8(7):609. https://doi.org/10.3390/children8070609

Molyneaux, E., Trevillion, K. & Howard, L.M. 2015. Antidepressant treatment for postnatal depression. *JAMA*, 313(19):1965-1966. https://doi.org/10.1001/jama.2015.2276

Moncrieff, J., Cooper, R.E., Stockmann, T., Amendola, S., Hengartner, M.P. & Horowitz, M.A. 2022. The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular psychiatry*:1-14. https://doi.org/10.1038/s41380-022-01661-0

Monroe, S.M., Slavich, G.M. & Gotlib, I.H. 2014. Life stress and family history for depression: The moderating role of past depressive episodes. *Journal of psychiatric research*, 49:90-95. https://doi.org/10.1016/j.jpsychires.2013.11.005

Mori, E., Iwata, H., Maehara, K., Sakajo, A. & Tamakoshi, K. 2018. Relationship between the mode of conception and depressive symptoms during the first 6 months post-partum in Japan. *Reproductive medicine and biology*, 17(3):275-282. https://doi.org/10.1002/rmb2.12101

Morris, M.J., Dausse, J.-P., Devynck, M.-A. & Meyer, P. 1980. Ontogeny of $\alpha_1$ and $\alpha_2$-adrenoceptors in rat brain. *Brain research bulletin*, 190(1):268-271. https://doi.org/10.1016/0006-8993(80)91178-6

Mughal, S., Azhar, Y. & Siddiqui, W. 2022. *Postpartum depression*. https://www.ncbi.nlm.nih.gov/books/NBK519070/ Date of access: 18 Sep 2023.

Murrin, L.C., Sanders, J.D. & Bylund, D.B. 2007. Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: Implications for differential drug effects on juveniles and adults. *Biochemical pharmacology*, 73(8):1225-1236. https://doi.org/10.1016/j.bcp.2007.01.028

Nakamura, S., Kimura, F. & Sakaguchi, T. 1987. Postnatal development of electrical activity in the locus ceruleus. *Journal of neurophysiology*, 58(3):510-524. https://doi.org/10.1152/jn.1987.58.3.510

Nduna, M., Jewkes, R.K., Dunkle, K.L., Jama Shai, N.P. & Colman, I. 2013. Prevalence and factors associated with depressive symptoms among young women and men in the Eastern Cape Province, South Africa. *Journal of child & adolescent mental health*, 25(1):43-54. https://doi.org/10.2989/17280583.2012.731410

Nelson, D.L., Herbet, A., Adrien, J., Bockaert, J. & Hamon, M. 1980. Serotonin-sensitive adenylate cyclase and [3H] serotonin binding sites in the CNS of the rat - II: Respective regional and subcellular distributions and ontogenetic developments. *Biochemical pharmacology*, 29(18):2455-2463. https://doi.org/10.1016/0006-2952(80)90349-4

Netsi, E., Pearson, R.M., Murray, L., Cooper, P., Craske, M.G. & Stein, A. 2018. Association of persistent and severe postnatal depression with child outcomes. *JAMA psychiatry*, 75(3):247-253. https://doi.org/10.1001/jamapsychiatry.2017.4363

O'Donnell, J.M., Bies, R.R. & Shelton, R.C. 2018. Drug therapy of depression and anxiety disorders. In: Brunton, L.L., ed. *Goodman & Gilman's The pharmacological basis of therapeutics*. 13th. New York, USA: McGraw-Hill. Chapter 15. pp. 267-277.

Oberholzer, I., Möller, M., Holland, B., Dean, O.M., Berk, M. & Harvey, B.H. 2018. *Garcinia mangostana Linn* displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders sensitive line rat. *Metabolic brain disease*, 33(2):467-480. https://doi.org/10.1007/s11011-017-0144-8

Oberlander, T.F., Grunau, R.E., Fitzgerald, C., Papsdorf, M., Rurak, D. & Riggs, W. 2005. Pain reactivity in 2-month-old infants after prenatal and postnatal selective serotonin reuptake inhibitor medication exposure. *Pediatrics*, 115(2):411-425. https://doi.org/10.1542/peds.2004-0420

Olivier, J.D., Valles, A., van Heesch, F., Afrasiab-Middelman, A., Roelofs, J.J., Jonkers, M., ... Kiliaan, A.J. 2011. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. *Psychopharmacology*, 217:419-432. https://doi.org/10.1007/s00213-011-2299-z

Oosthuizen, H. 2022. *The effects of post-partum fluoxetine and low intensity exercise on the depressive-like behaviour of FSL and FRL rats.* RSA: North-West University. (MSc dissertation).

Overpeck, M.D., Brenner, R.A., Trumble, A.C., Trifiletti, L.B. & Berendes, H.W. 1998. Risk factors for infant homicide in the United States. *New England journal of medicine*, 339(17):1211-1216. https://doi.org/10.1056/NEJM199810223391706

Overstreet, D.H. 1993. The Flinders sensitive line rats: a genetic animal model of depression. *Neuroscience & biobehavioral reviews*, 17(1):51-68. https://doi.org/10.1016/s0149-7634(05)80230-1

Overstreet, D.H. & Wegener, G. 2013. The Flinders sensitive line rat model of depression - 25 years and still producing. *Pharmacological reviews*, 65(1):143-155. https://doi.org/10.1124/pr.111.005397

Overstreet, D.H., Keeney, A. & Hogg, S. 2004. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. *European journal of pharmacology*, 492(2):195-201.

Pampaka, D., Papatheodorou, S.I., AlSeaidan, M., Al Wotayan, R., Wright, R.J., Buring, J.E., ... Christophi, C.A. 2019. Postnatal depressive symptoms in women with and without antenatal depressive symptoms: results from a prospective cohort study. *Archives of women's mental health*, 22:93-103. https://doi.org/10.1007/s00737-018-0880-8

Papa, S., Martino, P.L., Capitanio, G., Gaballo, A., De Rasmo, D., Signorile, A. & Petruzzella, V. 2012. The oxidative phosphorylation system in mammalian mitochondria. In: Scatena, R., Bottoni, P. & Giardina, B., eds. *Advances in mitochondrial medicine*. 942. Dordrecht: Springer Netherlands. pp. 3-37.

Park, S.-H. & Kim, J.-I. 2023. Predictive validity of the Edinburgh postnatal depression scale and other tools for screening depression in pregnant and postpartum women: a systematic review and meta-analysis. *Archives of gynecology and obstetrics*, 307(5):1331-1345. https://doi.org/10.1007/s00404-022-06525-0

Payne, J.L. 2021. Evaluating brexanolone for the treatment of postpartum depression. *Expert opinion on pharmacotherapy*, 22(8):959-964. https://doi.org/10.1080/14656566.2021.1897105

Payne, J.L. & Maguire, J. 2019. Pathophysiological mechanisms implicated in postpartum depression. *Frontiers in neuroendocrinology*, 52:165-180. https://doi.org/10.1016/j.yfrne.2018.12.001

Pei, L. & Wallace, D.C. 2018. Mitochondrial etiology of neuropsychiatric disorders. *Biological psychiatry*, 83(9):722-730. https://doi.org/10.1016/j.biopsych.2017.11.018

Pittman, R.N., Minneman, K.P. & Molinoff, P.B. 1980. Ontogeny of $\beta_1$-and $\beta_2$-adrenergic receptors in rat cerebellum and cerebral cortex. *Brain research*, 188(2):357-368. https://doi.org/10.1016/0006-8993(80)90037-2

Prady, S.L., Pickett, K.E., Gilbody, S., Petherick, E.S., Mason, D., Sheldon, T.A. & Wright, J. 2016. Variation and ethnic inequalities in treatment of common mental disorders before, during and after pregnancy: Combined analysis of routine and research data in the Born in Bradford cohort. *BioMed central psychiatry*, 16(1):99. https://doi.org/10.1186/s12888-016-0805-x https://10.1186/s12888-016-0805-x

Puyané, M., Subirà, S., Torres, A., Roca, A., Garcia-Esteve, L. & Gelabert, E. 2022. Personality traits as a risk factor for postpartum depression: a systematic review and meta-analysis. *Journal of affective disorders*, 298:577-589. https://doi.org/10.1016/j.jad.2021.11.010

Qaseem, A., Owens, D.K., Etxeandia-Ikobaltzeta, I., Tufte, J., Cross Jr, J.T., Wilt, T.J. & Clinical Guidelines Committee of the American College of Physicians. 2023. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. *Annals of internal medicine*, 176(2):239-252. https://doi.org/10.7326/M22-2056

Qiu, W., Hodges, T.E., Clark, E.L., Blankers, S.A. & Galea, L.A. 2020. Perinatal depression: heterogeneity of disease and in animal models. *Frontiers in neuroendocrinology*, 59:100854. https://doi.org/10.1016/j.yfrne.2020.100854

Rafferty, J., Mattson, G., Earls, M.F. & Yogman, M.W. 2019. Incorporating recognition and management of perinatal depression into pediatric practice. *Pediatrics*, 143(1), https://doi.org/10.1542/peds.2018-3259

Ray, M.T., Shannon Weickert, C. & Webster, M.J. 2014. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. *Translational psychiatry*, 4(5):e389. https://doi.org/10.1038/tp.2014.26

Rayen, I., Steinbusch, H.W., Charlier, T.D. & Pawluski, J.L. 2013. Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. *Psychoneuroendocrinology*, 38(9):1618-1629. https://doi.org/10.1016/j.psyneuen.2013.01.007

Rayen, I., Steinbusch, H.W., Charlier, T.D. & Pawluski, J.L. 2014. Developmental fluoxetine exposure facilitates sexual behavior in female offspring. *Psychopharmacology*, 231:123-133. https://doi.org/10.1007/s00213-013-3215-5

Rho, J.M. & Storey, T.W. 2001. Molecular ontogeny of major neurotransmitter receptor systems in the mammalian central nervous system: norepinephrine, dopamine, serotonin, acetylcholine, and glycine. *Journal of child neurology*, 16(4):271-280. https://doi.org/10.1177/088307380101600407

Robertson, E., Grace, S., Wallington, T. & Stewart, D.E. 2004. Antenatal risk factors for postpartum depression: a synthesis of recent literature. *General hospital psychiatry*, 26(4):289-295. https://doi.org/10.1016/j.genhosppsych.2004.02.006

Roets, M., Brand, L. & Steyn, S.F. 2023. Increased depressive-like behaviour of postpartum Flinders sensitive and resistant line rats is reversed by a predictable postpartum stressor. *Behavioural brain research*, 442:114321. https://doi.org/10.1016/j.bbr.2023.114321

Rolfe, D.F. & Brown, G.C. 1997. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiological reviews*, 77(3):731-758. https://doi.org/10.1152/physrev.1997.77.3.731

Roth, B.L., Hamblin, M.W. & Ciaranello, R.D. 1991. Developmental regulation of 5-$HT_2$ and 5-$HT_{1C}$ mRNA and receptor levels. *Developmental brain research*, 58(1):51-58. https://doi.org/10.1016/0165-3806(91)90236-c

Russell, R.W. & Overstreet, D.H. 1987. Mechanisms underlying sensitivity to organophosphorus anticholinesterase compounds. *Progress in neurobiology*, 28(2):97-129.

Sachs, H.C., Drugs, C.o., Frattarelli, D.A., Galinkin, J.L., Green, T.P., Johnson, T., ... Van den Anker, J. 2013. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics*, 132(3):e796-809. https://doi.org/0.1542/peds.2013-1985

Safi-Keykaleh, M., Aliakbari, F., Safarpour, H., Safari, M., Tahernejad, A., Sheikhbardsiri, H. & Sahebi, A. 2022. Prevalence of postpartum depression in women amid the COVID-19 pandemic: a systematic review and meta-analysis. *International journal of gynecology & obstetrics*, 157(2):240-247. https://doi.org/10.1002/ijgo.14129

Selph, S.S. & McDonagh, M.S. 2019. Depression in children and adolescents: evaluation and treatment. *American family physician*, 100(10):609-617.

Shabir, G.A. 2005. Step-by-step analytical methods validation and protocol in the quality system compliance industry. *Journal of validation technology*, 10:314-325.

Sharma, S. & Akundi, R.S. 2019. Mitochondria: a connecting link in the major depressive disorder jigsaw. *Current neuropharmacology*, 17(6):550-562. https://doi.org/10.2174/1570159X16666180302120322

Sheng, Z.-H. & Cai, Q. 2012. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. *Nature reviews neuroscience*, 13(2):77-93. https://doi.org/10.1038/nrn3156

Shorey, S., Chee, C.Y.I., Ng, E.D., Chan, Y.H., San Tam, W.W. & Chong, Y.S. 2018. Prevalence and incidence of postpartum depression among healthy mothers: a systematic review and meta-analysis. *Journal of psychiatric research*, 104:235-248. https://doi.org/10.1016/j.jpsychires.2018.08.001

Shrivastava, A. & Gupta, V.B. 2011. Methods for the determination of limit of detection and limit of quantitation of the analytical methods. *Chronicles of young scientists*, 2(1):21-25. https://doi.org/10.4103/2229-5186.79345

Sie, S., Wennink, J., Van Driel, J., te Winkel, A., Boer, K., Casteelen, G. & van Weissenbruch, M. 2012. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. *Archives of disease in childhood-fetal and neonatal edition*, 97(6):F472-F476. https://doi.org/10.1136/archdischild-2011-214239

Silva, A., Toffoli, L., Estrada, V., Veríssimo, L., Francis-Oliveira, J., Moreira, E., ... Pelosi, G. 2018. Maternal exposure to fluoxetine during gestation and lactation induces long lasting changes in the DNA methylation profile of offspring's brain and affects the social interaction of rat. *Brain research bulletin*, 142:409-413. https://doi.org/10.1016/j.brainresbull.2018.09.007

Slotkin, T.A., Kudlacz, E.M., Lappi, S.E., Tayyeb, M.I. & Seidler, F.J. 1990. Fetal terbutaline exposure causes selective postnatal increases in cerebellar α-adrenergic receptor binding. *Life sciences*, 47(22):2051-2057. https://doi.org/10.1016/0024-3205(90)90440-3

Spear, L.P. 2007. Assessment of adolescent neurotoxicity: rationale and methodological considerations. *Neurotoxicology and teratology*, 29(1):1-9. https://doi.org/10.1016/j.ntt.2006.11.006

Spinelli, M.G. 2004. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. *American journal of psychiatry*, 161(9):1548-1557. https://doi.org/10.1176/appi.ajp.161.9.1548

Steyn, S.F. 2018. *Chronic effects of pre-adolescent pharmacological and non-pharmacological interventions on depressive-like behaviour in rats.* Potchefstroom: North-West University. (PhD thesis). https://repository.nwu.ac.za/handle/10394/31194 Date of access: 02 Oct 2023.

Steyn, S.F., Harvey, B.H. & Brink, C.B. 2018. Immediate and long-term antidepressive-like effects of pre-pubertal escitalopram and omega-3 supplementation combination in young adult stress-sensitive rats. *Behavioural brain research*, 351:49-62. https://doi.org/10.1016/j.bbr.2018.05.021

Steyn, S.F., Harvey, B.H. & Brink, C.B. 2020. Pre-pubertal, low-intensity exercise does not require concomitant venlafaxine to induce robust, late-life antidepressant effects in Flinders sensitive line rats. *European journal of neuroscience*, 52(8):3979-3994. https://doi.org/10.1111/ejn.14757

Stiernborg, M., Efstathopoulos, P., Lennartsson, A., Lavebratt, C. & Mathé, A.A. 2022. Sirtuins and neuropeptide Y downregulation in Flinders sensitive line rat model of depression. *Acta Neuropsychiatrica*, 34(2):86-92. https://doi.org/10.1017/neu.2021.36

Sullivan, P.F., Neale, M.C. & Kendler, K.S. 2000. Genetic epidemiology of major depression: Review and meta-analysis. *American journal of psychiatry*, 157(10):1552-1562. https://10.1176/appi.ajp.157.10.1552

Susser, L.C., Sansone, S.A. & Hermann, A.D. 2016. Selective serotonin reuptake inhibitors for depression in pregnancy. *American journal of obstetrics and gynecology*, 215(6):722-730. https://doi.org/10.1016/j.ajog.2016.07.011

Taddio, A., Ito, S. & Koren, G. 1996. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. *The Journal of clinical pharmacology*, 36(1):42-47. https://doi.org/10.1002/j.1552-4604.1996.tb04150.x

Thomas, S.A., Matsumoto, A.M. & Palmiter, R.D. 1995. Noradrenaline is essential for mouse fetal development. *Nature*, 374(6523):643-646. https://doi.org/10.1038/374643a0

Tietz, A., Zietlow, A.L. & Reck, C. 2014. Maternal bonding in mothers with postpartum anxiety disorder: the crucial role of subclinical depressive symptoms and maternal avoidance behaviour. *Archives of women's mental health*, 17(5):433-442. https://10.1007/s00737-014-0423-x

Tillmann, S. & Wegener, G. 2019. Probiotics reduce risk-taking behavior in the elevated plus maze in the Flinders sensitive line rat model of depression. *Behavioural brain research*, 359:755-762. https://doi.org/10.1016/j.bbr.2018.08.025

Tillmann, S., Happ, D.F., Mikkelsen, P.F., Geisel, J., Wegener, G. & Obeid, R. 2019. Behavioral and metabolic effects of S-adenosylmethionine and imipramine in the Flinders sensitive line rat model of depression. *Behavioural brain research*, 364:274-280. https://doi.org/10.1016/j.bbr.2019.02.011

Tissari, A.H. 1975. Pharmacological and ultrastructural maturation of serotonergic synapses during ontogeny. *Medical biology*, 53(1):1-14.

Toffoli, L., Rodrigues Jr, G., Oliveira, J., Silva, A., Moreira, E., Pelosi, G. & Gomes, M. 2014. Maternal exposure to fluoxetine during gestation and lactation affects the DNA methylation programming of rat's offspring: modulation by folic acid supplementation. *Behavioural brain research*, 265:142-147. https://doi.org/10.1016/j.bbr.2014.02.031

Trujillo, J., Vieira, M.C., Lepsch, J., Rebelo, F., Poston, L., Pasupathy, D. & Kac, G. 2018. A systematic review of the associations between maternal nutritional biomarkers and depression and/or anxiety during pregnancy and postpartum. *Journal of affective disorders*, 232:185-203. https://doi.org/10.1016/j.jad.2018.02.004

Tse, G., Yan, B.P., Chan, Y.W., Tian, X.Y. & Huang, Y. 2016. Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac arrhythmogenesis. *Frontiers in physiology*, 7:313. https://doi.org/10.3389/fphys.2016.00313

Turrens, J.F. 2003. Mitochondrial formation of reactive oxygen species. *The Journal of physiology*, 552(2):335-344. https://doi.org/10.1111/j.1469-7793.2003.00335.x

U.S. Food & Drug Administration. 2018. *Bioanalytical method validation guidance for industry*. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry Date of access: 14 Sep 2023.

U.S. Food & Drug Administration. 2019. *FDA approves first treatment for post-partum depression*. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression Date of access: 18 Sep 2023.

Uys, M.M., Shahid, M., Sallinen, J. & Harvey, B.H. 2017. The $\alpha_{2C}$-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. *Behavioural pharmacology*, 28(1):9-18. https://doi.org/10.1097/FBP.0000000000000261

van de Merbel, N.C. 2008. Quantitative determination of endogenous compounds in biological samples using chromatographic techniques. *TrAC Trends in analytical chemistry*, 27(10):924-933. https://doi.org/10.1016/j.trac.2008.09.002

van den Berg, A.M. 2020. Major depressive disorder. In: Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D. & Ellingrod, V.L., eds. *Pharmacotherapy: a pathophysiologic approach*. 11th. USA: McGraw-Hill. Chapter 85. p *ebook*. https://accesspharmacy-mhmedical-com.nwulib.idm.oclc.org/book.aspx?bookid=2577 Date of access: 20 Sep 2023.

Vasupanrajit, A., Jirakran, K., Tunvirachaisakul, C., Solmi, M. & Maes, M. 2022. Inflammation and nitro-oxidative stress in current suicidal attempts and current suicidal ideation: a systematic review and meta-analysis. *Molecular psychiatry*, 27(3):1350-1361. https://doi.org/10.1038/s41380-021-01407-4

Vernon, M.M., Young-Hyman, D. & Looney, S.W. 2010. Maternal stress, physical activity, and body mass index during new mothers' first year postpartum. *Women & health*, 50(6):544-562. https://doi.org/10.1080/03630242.2010.516692

Wald, J., Henningsson, A., Hanze, E., Hoffmann, E., Li, H., Colquhoun, H. & Deligiannidis, K.M. 2022. Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose. *Clinical pharmacokinetics*, 61(9):1307-1319. https://doi.org/10.1007/s40262-022-01155-w

Walf, A.A. & Frye, C.A. 2006. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. *Neuropsychopharmacology*, 31(6):1097-1111. https://doi.org/10.1038/sj.npp.1301067

Wallace, J.A. & Lauder, J.M. 1983. Development of the serotonergic system in the rat embryo: an immunocytochemical study. *Brain research bulletin*, 10(4):459-479. https://doi.org/10.1016/0361-9230(83)90144-2

Walton, N. & Maguire, J. 2019. Allopregnanolone-based treatments for postpartum depression: why/how do they work? *Neurobiology of stress*, 11:100198. https://doi.org/10.1016/j.ynstr.2019.100198

Watkins, S., Meltzer-Brody, S., Zolnoun, D. & Stuebe, A. 2011. Early breastfeeding experiences and postpartum depression. *Obstetrics & gynecology*, 118(2 Part 1):214-221. https://doi.org/10.1097/AOG.0b013e3182260a2d

Wei, Y., Liu, J., Villaescusa, J., Åberg, E., Brené, S., Wegener, G., ... Lavebratt, C. 2016. Elevation of IL6 is associated with disturbed let-7 biogenesis in a genetic model of depression. *Translational psychiatry*, 6(8):e869-e869. https://doi.org/10.1038/tp.2016.136

Wei, Y.B., Melas, P.A., Wegener, G., Mathé, A.A. & Lavebratt, C. 2015. Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the BDNF gene. *International journal of neuropsychopharmacology*, 18(2), https://doi.org/10.1093/ijnp/pyu032

Weissman, A.M., Levy, B.T., Hartz, A.J., Bentler, S., Donohue, M., Ellingrod, V.L. & Wisner, K.L. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. *American journal of psychiatry*, 161(6):1066-1078. https://doi.org/10.1176/appi.ajp.161.6.1066

Whitaker-Azmitia, P.M. 2005. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? *International journal of developmental neuroscience*, 23(1):75-83.

Whitney, A., Lindeque, J.Z., Kruger, R. & Steyn, S.F. 2023a. Running from depression: the antidepressant-like potential of prenatal and pre-pubertal exercise in adolescent FSL rats exposed to an early-life stressor. *Acta Neuropsychiatrica*:1-15. https://doi.org/10.1017/neu.2023.52

Whitney, A., Lindeque, J.Z., Kruger, R. & Steyn, S.F. 2023b. Genetically predisposed and resilient animal models of depression reveal divergent responses to early-life adversity. *Acta Neuropsychiatrica*:1-13. https://doi.org/10.1017/neu.2023.37

Winzer-Serhan, U., Raymon, H., Broide, R., Chen, Y. & Leslie, F. 1996a. Expression of $\alpha_2$ adrenoceptors during rat brain development - I. $\alpha_{2A}$ messenger RNA expression. *Neuroscience*, 76(1):241-260. https://doi.org/10.1016/S0306-4522(96)00368-5

Winzer-Serhan, U.H. & Leslie, F.M. 1997. $\alpha_{2B}$ Adrenoceptor mRNA expression during rat brain development. *Developmental brain research*, 100(1):90-100. https://doi.org/10.1016/s0165-3806(97)00035-7

Winzer-Serhan, U.H., Raymon, H.K., Broide, R.S., Chen, Y. & Leslie, F.M. 1996b. Expression of $\alpha_2$ adrenoceptors during rat brain development - II. $\alpha_{2C}$ messenger RNA expression and [3H] rauwolscine binding. *Neuroscience*, 76(1):261-272. https://doi.org/10.1016/S0306-4522(96)00369-7

World Health Organization. 2019. *ICD-10 version: 2019*. https://icd.who.int/browse10/2019/en#/F50-F59 Date of access: 18 Sep 2023.

World Health Organization. 2022. *Adolescent mental health*. https://www.who.int/news-room/fact-sheets/detail/adolescent-mental-health Date of access: 14 Sep 2023.

Wu, T., Huang, Y., Gong, Y., Xu, Y., Lu, J., Sheng, H. & Ni, X. 2019. Treadmill exercise ameliorates depression-like behavior in the rats with prenatal dexamethasone exposure: the role of hippocampal mitochondria. *Frontiers in neuroscience*, 13:264. https://doi.org/10.3389/fnins.2019.00264

Wu, Y., Zhang, C., Liu, H., Duan, C., Li, C., Fan, J., ... Li, X. 2020. Perinatal depressive and anxiety symptoms of pregnant women along with COVID-19 outbreak in China. *American journal of obstetrics and gynecology*, 223(2):e1-240.e249. https://doi.org/10.1016/j.ajog.2020.05.009

Yim, I.S., Glynn, L.M., Schetter, C.D., Hobel, C.J., Chicz-DeMet, A. & Sandman, C.A. 2009. Elevated corticotropin-releasing hormone in human pregnancy increases the risk of postpartum depressive symptoms. *Archives of general psychiatry*, 66(2):162. https://soi.org/10.1001/archgenpsychiatry.2008.533

Yu, Y., Herman, P., Rothman, D.L., Agarwal, D. & Hyder, F. 2018. Evaluating the gray and white matter energy budgets of human brain function. *Journal of cerebral blood flow & metabolism*, 38(8):1339-1353. https://doi.org/10.1177/0271678X17708691

Zaccarelli-Magalhães, J., Santoro, M.A., de Abreu, G.R., Ricci, E.L., Fukushima, A.R., Kirsten, T.B., ... de Souza Spinosa, H. 2020. Exposure of dams to fluoxetine during lactation disturbs maternal behavior but had no effect on the offspring behavior. *Behavioural brain research*, 377:112246. https://doi.org/10.1016/j.bbr.2019.112246

Zambaldi, C.F., Cantilino, A., Montenegro, A.C., Paes, J.A., de Albuquerque, T.L.C. & Sougey, E.B. 2009. Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. *Comprehensive psychiatry*, 50(6):503-509. https://doi.org/10.1016/j.comppsych.2008.11.014

Zhang, X., Norris, S.L., Gregg, E.W., Cheng, Y.J., Beckles, G. & Kahn, H.S. 2005. Depressive symptoms and mortality among persons with and without diabetes. *American journal of epidemiology*, 161(7):652-660. https://doi.org/10.1093/aje/kwi089

Zhao, R., Zhou, Y., Shi, H., Ye, W., Lyu, Y., Wen, Z., ... Xu, Y. 2022. Effect of gestational diabetes on postpartum depression-like behavior in rats and its mechanism. *Nutrients*, 14(6):1229. https://doi.org/10.3390/nu14061229

Zheng, W., Cai, D.-B., Sim, K., Ungvari, G.S., Peng, X.-J., Ning, Y.-P., ... Xiang, Y.-T. 2019. Brexanolone for postpartum depression: a meta-analysis of randomized controlled studies. *Psychiatry research*, 279:83-89. https://doi.org/10.1016/j.psychres.2019.07.006

Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J., ... Kizek, R. 2012. Redox status expressed as GSH: GSSG ratio as a marker for oxidative stress in paediatric tumour patients. *Oncology letters*, 4(6):1247-1253. https://doi.org/10.3892/ol.2012.931

Zonana, J. & Gorman, J.M. 2005. The neurobiology of postpartum depression. *CNS spectrums*, 10(10):792-799. https://doi.org/10.1017/S1092852900010312